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Introduction
The history of autoimmunity is almost as old as the history of immunology. In 1890 Beh-
ring and Kitisato [1], working in Koch’s institute, demonstrated that the serum of animals
immunized against attenuated diphtheria toxins can be used as a preventive or therapeutic
inoculation against diphtheria in other animals through a specific neutralization of the tox-
in of the disease. This discovery initiated the long history of the elucidation of the immune
response. Just 10 years later Metalnikof [2] challenged the possibility of an immune re-
sponse against self-constituents of the organism on the basis of his studies on guinea pigs
immunized with spermatozoids. A few years later Chauffard and Vincent [3] reported the
first case of autoimmune hemolytic anemia (AIHA) and Fiessinger [4] described anti-liver
antibodies in patients suffering from chronic active hepatitis (CAH). Nevertheless, in the
1950s the idea of the immune apparatus being used against self-antigens was still consid-
ered absurd. The very existence of autoimmune disorders was questioned. Until recently,
multiple sclerosis (MS) was considered a viral disease, and rheumatoid arthritis (RA) and
systemic lupus erythematosus (SLE) to be caused by infectious agents, especially of the
mycoplasma family. Interest in autoimmune diseases grew slowly but constantly in view
of the intensive research being carried out in experimental animals as well the clinical re-
search being carried out on thyroid disorders, RA, SLE, and MS.
It is now known that autoimmunity is not a rare event as was thought 50 years ago but
is a frequent condition with over 40 recognized autoimmune diseases affecting more than
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6% of the general population. Despite this development treatment of patients suffering
from autoimmune diseases remains a very difficult domain. First, it is not easy for clini-
cians to follow the remarkable progress made in the field of molecular and cellular immu-
nology. Furthermore, new discoveries in experimental immunology have made it neces-
sary to change “accepted concepts” every 5 or 10 years. Secondly, autoimmune diseases
are spread over 12–15 different clinical compartments, each concentrating on its own terri-
tory and not taking advantage of progress made in the other compartments. In addition,
new immunomodulatory drugs are made available to the clinician only for specific indica-
tions and not for the inherent use of immunomodulation. For all these reasons we are still
a long way from formulating a “unified” concept in the treatment of autoimmune diseases.
This review is intended for clinicians. Indeed, the development of our knowledge in the
field of immunology has reached a level which is unattainable by the majority of practic-
ing clinicians; yet it is the clinician who must take care of patients suffering from disorders
of the immune system. Accordingly, we have revisited many areas which may appear triv-
ial to the modern immunologist, but which need to be made clear to the clinician who must
understand the complex mechanisms involved in immunopathology in order to offer an ef-
fective therapy to his patients.
This review begins with a short history of the events leading to today’s molecular un-
derstanding of the immune response. From the plethora of scientific information we have
chosen those crucial discoveries which help the clinician in the management of autoim-
mune disorders. In particular, the clinician must consider the type of immune response in-
volved in the autoantigen-driven immunopathology and be aware of the kinetics of molec-
ular and cellular events in the attempt to attenuate, correct, or limit the aberrant autoim-
mune response. Furthermore, one must bear in mind the clonal expansion of engaged T
and B lymphocytes, essential for fighting infection but potentially detrimental in the
course of the autoimmune response. Early intervention is indicated not only for this reason
but also to prevent irreparable tissue damage. Furthermore, treatment must consider caus-
ative and disease-modifying environmental factors. With today’s understanding of the im-
mune response, its genetic background, and the importance of environmental factors, it
has now become possible to establish a rational treatment regimen for the management of
autoimmune diseases.
The second half of this review summarizes our personal experience in treatment of au-
toimmune diseases over the past 50 years, during which time the number of immunomod-
ulating drugs has substantially increased. The great number of drugs with different mecha-
nisms of action has enriched the overall therapeutic potential. The choice of drugs is cru-
cial for treatment success. We discuss the selection of approriate immunosuppressive
drugs and strategies of treatment (early intervention, remission-induction regimens, long-
term maintenance treatment), monitoring of drug toxicity, and importance of environmen-
tal factors.
A short history of immunology
For the first 50 years of its development our knowledge concerning immunity was restrict-
ed to humoral immunity, i.e., immunity mediated by serum antibodies. Ten years after the
discovery of antisera by Behring and Kitisato, Bordet [5] described a heat labile factor
necessary for bacteriolysis to occur with specific antisera. This factor, called complement,
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proved to be most relevant both for the defense mechanism and for the pathogenesis of
autoimmune diseases. The question as to which cells produce antibodies remained unan-
swered until 1948 when Fagreus [6] discovered the plasmacellular origin of antibodies.
Eight years later Glick et al. [7] discovered the role of the bursa of Fabricius in the devel-
opment of humoral immunity in the chicken, a breakthrough which led to the term B lym-
phocytes. In humans B lymphocytes have a function similar to that of B lymphocytes in
the chicken, although no certain equivalent specific B cell organ has been found.
In 1945 Chase [8] opened the field of cellular immunity with his experiments on the
cellular transfer of cutaneous hypersensitivity to tuberculin. This cellular immunity was
considered to represent “cell-bound antibodies,” similar to serum antibodies but still fixed
to the surface of the lymphocyte. Fifteen years later Benacerraf and Gell [9] came to a dif-
ferent conclusion. The results of sophisticated experiments in guinea pigs indicated that
the differences in immunological specificity between delayed hypersensitivity and anti-
body-mediated reactions reflect fundamental differences in the nature of the recognition
process. The sensitized cells recognize antigen by a mechanism other than having specific
antibody on their surface; an antigen-specific receptor was thus postulated. The role of the
thymus in the development of immunological capacity, first discovered by Miller [10] in
1961, opened the door to the recognition of the lymphocyte population responsible for cel-
lular immunity (T lymphocytes; see [11]).
The next breakthrough was made in 1972 by Benacerraf and McDevitt [12] with the
discovery of the immune response genes. The monocytes emerged finally from a “labor
status,” only passively involved in defense reactions, to a fundamental and primary status,
essential for initiating a specific immune response, including autoimmune responses.
These immune response genes belong to the major histocompatibility complex (MHC)
gene. Five years later Zinkernagel and Doherty [13] described the MHC requirement for T
cell mediated lysis of target cells infected with lymphocytic choriomeningitis virus.
With the help of surface markers it became possible to differentiate various T cell sub-
populations. A first separation was made with two different anti-leukocyte antibodies,
anti-Leu2a and anti-Leu3a. The Leu3a population was subsequently named “T4 helper
cells” and the Leu2a population “T8 suppressor/cytotoxic T cells.” Further systematic
search for additional surface markers of lymphocytes, monocytes, granulocytes, and endo-
thelial cells was carried out using monoclonal antibodies. The ensuing CD (cluster of dif-
ferentiation) system today encompasses more than 100 different markers. Of special inter-
est to clinical immunology are the CD4 (T4) helper cells which recognize the antigenic
target in association with immune response gene markers of the MHC class II type, and
CD8 (T8) cells which recognize the antigenic target in association with the MHC class I
type. With regard to B lymphocytes, the CD20 marker has become a specific target in the
treatment of B cell lymphoma and possibly in the treatment of B cell dependent autoim-
mune disorders (Rituximab, a genetically engineered chimeric murine/human monoclonal
antibody directed against the CD20 antigen present on the surface of normal and malig-
nant B lymphocytes).
Research on cytokines, which are involved in cellular development and differentiation,
led to another fundamental discovery. In 1986 Mosmann and Coffman [14] discovered
two different subsets of T helper (Th helper) cells. Depending on the cytokines involved
in the immune response, one of the two types prevails. In general, it has been considered
that Th1 and Th2 cells are fundamental for cellular and humoral immunity, respectively.
The role of Th1 cytokines in the switch from IgM to complement-fixing IgG antibodies
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additionally emphasizes the implication of Th1 immune responses in the generation of cy-
totoxic antibodies.
Another development relevant to clinical immunology concerns transplantation immu-
nology. In 1953 Billingham et al. [15] recognized that antigens responsible for graft rejec-
tion reside in leukocytes. Actively acquired tolerance with regard to incompatible skin
grafts was obtained by the injection of spleen cells of the donor’s A strain into mouse em-
bryos of the recipient’s CBA strain in utero. The tolerance thus induced was specific since
CBA mice tolerant of A-strain tissues easily reject allografts from other unrelated strains.
In 1955 Gorer [16] reported leukoagglutinins developing in the recipients of skin allografts
which reacted with cells of the donor strains. These results created interest in the MHC in
human leukocytes. The first evidence of different leukocyte groups in humans emerged in
1954 [17]. Much work was subsequently carried on this topic by Dausset [18], leading to
the definition of the human leukocyte antigen (HLA) system. It is not surprising that the
genes controlling the HLA network are the same as the immune response genes of Benac-
erraf, which proved to be fundamental in the genetic predisposition to autoimmune dis-
eases.
The immune response
The immune response is the key event in the development of immunity. It involves a most
sophisticated interaction between the three pillars of immunity: the antigen-presenting
cells (APC), T lymphocytes, and B lymphocytes (Fig. 1). In a first step the antigen in
question (usually a protein) must be captured and metabolized into peptides by the APC.
If a peptide of the metabolized antigen is recognized by a molecule of the MHC class II
Fig. 1 Schematic representation of antigen recognition in T-dependent B cell activation. The dentritic cells
(DC), the antigen presenting cells for the T cell activation, internalize antigen and, by enzymatic process-
ing, generate peptides which bind to MHC class II molecules, i.e. peptides which serve as T-epitopes. Rec-
ognition of the MHC-peptide complexes by the T cell antigen receceptors (TCR), together with the costim-
ulatory signals generated by the activated DC, leads to T helper cell activation. The B cell antigen receptors
(membrane immunoglobine, Ig) recognize B-epitopes of the antigen. Ig-bound antigen is internalized by
the B cell and, like in DC, processed. If a B cell presents an MHC-peptide complex recognized by an acti-
vated T helper cell, it receives stimulatory signals for its own activation.
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complex, this antigenic peptide in association with MHC class II is transported at the sur-
face of the APC and presented to CD4 T lymphocytes exhibiting the specific receptor for
the antigenic peptide-MHC complex. This interaction, with the help of costimulatory mo-
lecules (B7 on APC and CD28 on T cells), activates the CD4 T lymphocyte resulting in
clonal expansion. B lymphocytes specifically recognize the antigen by the B cell antigen
receptor, followed by its internalization and subsequent degradation, as in the case of
APC, the B lymphocytes themselves assuming the role of the APC. Such an antigen-spe-
cific B lymphocyte must be activated through the interaction with specific CD4 T lympho-
cytes in order also to enter the clonal expansion cycle. By this mechanism the organism
builds up an impressive army of antigen-specific T and B cells in 7–10 days, necessary to
fight an infectious agent. The nature of this army depends on a number of factors.
If the initial step of the immune response triggers and favors the production of interleu-
kin (IL) 12 by APC such as dendritic cells (DC), which probably depends on the type of
invading pathogen, development of Th0 into Th1 lymphocytes is induced (e.g., in tubercu-
losis), with only minor development of Th2 lymphocytes. These Th1 cells release interfer-
on (IFN) g, IL-2, and tumor necrosis factor (TNF) a, resulting in an explosive battle with
the aggressive microbe by activating macrophages, promoting cytotoxic CD8 T cell re-
sponses, and inducing complement-binding cytotoxic IgG antibodies, at the cost, however,
of damage to the surrounding tissue. If IL-12 production by DC is limited in the initial
stages of the immune response, IL-4 production (although its cellular origin remains to be
determined) favors the development of Th2 immunity. Activated Th2 cells preferentially
secrete IL-4, IL-5, and IL-13, leading to the production of non-complement binding IgG
and IgE.
The type of Th development also depends on the localization of the immune response.
In particular, DC engaged in mucosal immunity play an important role in the regulation of
the immune response. The intestine is home to a complex microflora with 300–400 differ-
ent bacterial species. The mucosal immune system is the primary defense against numer-
ous pathogens, not only in the gastrointestinal tract but also in the respiratory tract. The
defense within such a vulnerable environment needs a very fine tuning of CD4 T lympho-
cytes with limited inflammation. On the one hand, DC in Peyer’s patches apparently play
an important role in directing Th development in three directions: the development of the
Th1 pathway, the development of the Th2 pathway, and the induction of IL-10 mediated
mucosal tolerance by regulatory T lymphocytes. On the other hand, IgA specifically se-
creted in the mucosal immune system permits the neutralization and elimination of antigen
(without relevant inflammation).
The distinction between Th1 and Th2 immune responses has contributed greatly to our
understanding of immunopathological conditions, but it should be borne in mind that we
are dealing with a very dynamic biological system which involves parallel Th1 and Th2
pathways. In the case of childhood idiopathic thrombocytopenic purpura (ITP) Mouzaki et
al. [19] have shown this flexibility of the expression pattern of Th1 and Th2 cytokine
genes. In their series of patients the Th1 dominant form has been shown to be more resis-
tant to high-dose Ig treatment than the Th2 dominant form.
In the Th1 immune response the CD4 T cells involved in the afferent pathway can also
be engaged in the efferent pathway, i.e., in the cellular defense mechanism with MHC
class II dependent antimicrobial activity. However, cellular immunity involves mostly cy-
totoxic CD8 T lymphocytes, i.e., cells with a different T cell receptor (TCR), and with his-
tocompatibility class I dependency. It has been shown that the immune response can also
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be initiated through the interaction of CD8 T lymphocytes with antigens presented by
MHC class I molecules without the help of CD4 T lymphocytes.
In the field of autoimmunity one deals with similar pathways of the immune response.
Some autoimmune phenomena show a MHC class II dependence and others a class I de-
pendence, with the involvement of either CD4 or CD8 T cells.
Autoimmunity
The possibility of misusing the immune system against self-constituents was considered as
early as the first few years following the discovery of the humoral immune response. Nev-
ertheless, it was several decades before physicians in the fields of research and clinical
medicine accepted this type of pathology, except for extremely rare instances such as cer-
tain forms of hemolytic anemia. After the introduction of the antiglobulin test by Coombs
et al. [20] in 1945 AIHA finally entered hematology as a recognized autoimmune condi-
tion. Other, more frequent conditions, such as RA and MS had to wait many more years
before acquiring such recognition.
In 1942 Klemperer et al. [21] published their concept of “collagen disease,” encom-
passing various pathologies all exhibiting significant alterations in the connective tissue,
especially fibrinoid necrosis within the walls of arterioles and small arteries but also mem-
branes such as the pleura, pericardium, and joint capsules. Subsequent analysis showed
these structures to be rich in gammaglobulins, suggesting a hypersensitivity condition.
This concept was stimulating and appealing to clinicians who rapidly accepted this term to
designate a specific pathology, rather to the dismay of Klemperer et al. who had intended
it to be used in purely topographic terms. However, it proved to be a most constructive
concept with growing evidence of autoimmunity as the prevalent factor in the pathogene-
sis of most of these disorders.
The discovery of the “LE cell phenomenon” in 1948 by Hargraves et al. [22] paved the
way for more specific research on SLE, a “prototype” of collagen disease. In particular,
the factor responsible for the LE cell was shown to be a gammaglobulin. The fact that this
factor is absorbable on isolated cell nuclei, but not on intact cells, revealed its anti-nuclear
antibody nature [23]. Since it does not react with intact cells, the LE factor cannot be di-
rectly responsible for cellular or tissue damage. The target of the LE cell factor proved to
be deoxyribonucleoprotein. Further work led to the detection of antibodies against the con-
stituents of nucleoprotein, DNA [24] and histone [25]. While these antibodies are not di-
rectly implicated in the mechanisms of tissue damage, they were later found to be impli-
cated in the “immune complex pathology.”
The discovery of the rheumatoid factor (RF) opened another large area of research on
RA, the most important of the collagen diseases. In 1940 Waaler [26] reported a factor in
human serum which activated the specific agglutination of sheep erythrocytes. In 1948
Rose et al. [27] studied in greater depth this phenomenon of differential agglutination of
normal and sensitized sheep erythrocytes by sera of patients with RA. In subsequent stud-
ies this RF proved to be an autoantibody against “aggregated” IgG. Clinicians believed the
RF to be a causative element for the disease, despite observations that this factor appears,
if ever, only months after onset of the disease. It may also be present without RA. Never-
theless, the discovery of the RF proved very stimulating for research on the structure of
immunoglobulin. All attempts to find a causative infectious agent for RA failed. After dec-
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ades of intense research, RA is now recognized as a chronic inflammatory autoimmune
disease, targeting articular structures (collagen II or a degradation product?) on the basis
of a complex genetic disorder. In particular, immune response genes of the HLA-DR4
family are involved. Today one recognizes the correlation between various clinical forms
of synovitis and disease-associated HLA alleles. Polymorphism of the HLA-DRB1 genes
appears to predict clinical manifestations of the disease [28]. In fact, RA is not a distinct,
well-defined disease, but rather a spectrum of different subtypes with erosive and nonero-
sive forms and with various patterns of joint involvement. Similar conclusions can be ap-
plied to SLE [29]; various clinical phenotypes occur in both conditions.
Recent decades have witnessed a much wider acceptance of the existence of autoanti-
bodies. The reasons for this are partly technical, partly conceptual. On the technical side
the sensitivity of methods for the detection of antibodies has increased tremendously, re-
sulting in an unexpectedly large number of different autoantibodies in conditions thought
to be due to autoimmunity. Side by side with the progress in the detection of autoantibod-
ies, the concept of autoimmunity has become increasingly accepted. Indeed, the list of “ac-
cepted” autoimmune diseases has grown to more than 40 different entities (see “Appen-
dix”). In most of them we do not know whether the autoantibodies are directly involved in
the pathogenesis of the disease, or whether they are the consequence of the immunopatho-
logical processes involved. However, the detection of these antibodies has become very
useful in diagnostic terms, much less for the assessment of disease activity. Furthermore
their absence does not exclude the existence of autoimmune disease.
At first, clinicians thought that the presence of autoantibodies implied their direct role
in the disease process. Today we are more critical, especially in view of the question as to
whether a disease process, thought to be autoimmune in nature, is mediated by a humoral
or a cellular immune process. Answering this question is rendered difficult by the lack of
diagnostic T cell markers. Extensive studies with animal models of autoimmune diseases
have shown that T cell immune processes are relevant in most organ-specific autoimmune
conditions such as diabetes, arthritis, experimental autoimmune encephalitis, and experi-
mental autoimmune thyroiditis. Disease specific T cell markers had to be postulated, and
well documented in some animal models, particularly in autoimmune encephalitis.
Mechanisms of cellular and tissue damage in autoimmune diseases
Antibody-mediated conditions
Since antibodies are the product of B lymphocytes, clinicians have been tempted to con-
sider autoantibody-mediated conditions as “pure” B cell pathologies. However, research
on the immune response has clearly demonstrated the T cell dependency of B cell expan-
sion. B lymphocytes have the potential to develop antibody-specificity to an almost unlim-
ited extent, including against self-constituents, in part due to the mechanism of somatic
hypermutation of the genes responsible for antibody specificity. It is exactly this T cell de-
pendency of B cell activation which protects the organism from the expansion of potential-
ly dangerous autoreactive B cells. Genes responsible for the T cell receptor do not undergo
somatic mutations; on the contrary, they remain stable throughout life. Potentially danger-
ous autoreactive T cells are eliminated by the thymus at the very beginning of develop-
ment of the immune system. An interesting example of an aberrant thymic function lead-
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ing to pathogenic autoantibodies is myasthenia gravis (MY), an antibody-dependent dis-
ease which responds in some thymoma patients to the elimination of the thymic tumor. T
cells are thus of primary importance also in antibody-mediated pathologies, and must be
included in the treatment strategy of autoantibody-mediated conditions.
Antibodies can exhibit pathogenicity by acting directly on target cells (cytotoxic activi-
ty) or target structures (e.g., acetylcholine receptor), or they may act indirectly in the form
of antigen-antibody complexes. Autoimmune hemolytic anemia, thrombocytopenia and
leukopenia are classical examples of antibody-mediated cytotoxic conditions. The patho-
genicity of these antibodies depends on various features such as binding strength, comple-
ment fixation, and interaction with IgG Fc receptors as well as on the antigenic determi-
nant of the target cell. Thus, patients may develop antibodies to a red cell constituent (usu-
ally the basic Rh antigen), initially without hemolytic anemia, with low-affinity antibodies
bound to red cells and eventually with increased antibody production of increasing binding
strength, finally with excess “free” autoantibodies detectable in the serum of these pa-
tients. Such a development reflects the phenomenon of clonal expansion of autoreactive B
cells with increasing binding affinity, stressing the conclusion that we are dealing with an
autoantigen-driven immune response.
In 1924 in his studies on the Arthus phenomenon, Opie [30] was the first to demon-
strate that antibodies indirectly produce inflammatory tissue lesions. Twenty-three years
later Germuth and McKinnon [31] demonstrated the role of antigen-antibody complexes
in the experimental serum sickness model, which has become the prototype of immune
complex disease [32]. At the same time Miescher et al. [33] demonstrated the action of
soluble immune complexes on leukocytes and thrombocytes, leading to leuko- and throm-
bocytopenia of experimental serum sickness. In 1957 Mellors et al. [34] demonstrated Ig
deposits in lupus nephritis. Ever since then an immune complex pathology has been be-
lieved to play a major part in conditions in which Ig deposits are detected in the affected
tissues (SLE, panarteritis nodosa, certain types of cutaneous vasculitis).
T cell mediated pathology
All the serological parameters for the diagnosis of autoimmune disorders belong to humor-
al immunology, i.e., to the B lymphocyte lineage. With these serological parameters to
hand, clinicians were tempted to consider their role in pathogenetic terms. However, with
regard to collagen diseases these serological parameters are not directly implicated in the
pathogenesis of disease but are more likely the consequence of the immune conflict. This
does not exclude their participation in the disease process.
With the lack of diagnostic procedures for the detection of disease-specific T cell re-
ceptors T cell pathology has long been neglected. In this respect the study of experimental
models that demonstrated the primordial role of cells, for example, collagen-induced ar-
thritis, autoimmune encephalitis, autoimmune thyroiditis, and autoimmune diabetes, has
been of great help. These pathologies were attributed to “cellular immunopathology,” in
contrast to “humoral immunopathology.” The histological features of these conditions at-
tributable to cellular immunopathology show a granulomatous pattern with the participa-
tion of macrophages, T and B lymphocytes. With the recognition of two different Th cells,
Th1 and Th2, the question of cellular immunopathology had to be reassessed. Th1 and
Th2 pathways involve different cytokines and different antibody responses, responding
differently to immunodulatory treatments. Different treatment regimens must thus be de-
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signed for Th1 and Th2 pathologies. In particular, the localized Th1 immune conflict in
patients with RA liberates TNF in sufficient concentrations to produce inflammation, pain,
and tissue damage.
Similar events occur in other granulomatous inflammatory conditions such as Crohn’s
disease, ulcerative colitis (UC), and ankylosing spondyloarthritis (AS). In these conditions
a positive response to anti-TNF treatment is limited to acute phases of the disease. In the
attempt to separate Th1 from Th2 pathology it must be remembered that a given immune
response is rarely limited to one of the two pathways. For example, in RA, a preferential
Th1 condition, the periarticular pannus contains T and B lymphocytes, while immune
complexes are detectable in the synovial fluid.
IL-10 has become an important target of research on the Th1/Th2 balance. The key
function of IL-10 is to inhibit cytokine synthesis of Th1 cells, thus exerting a suppressive
function on the Th1 pathway. Furthermore, IL-10 has been shown to be involved in the
development of mucosal tolerance. A classical example of this role of IL-10 is seen in pa-
tients with RA: diminution of IL-10 blood levels reflects disease activity; administration
of IL-10 attenuates the disease symptoms, as should happen in a Th1 pathology. Neverthe-
less, we cannot conclude that conditions with an elevated serum IL-10 level necessarily
belong to the Th2 pathology.
In the case of SLE IL-10 levels are increased and are correlated with disease activity.
Furthermore, anti-TNF treatment, beneficial in the Th1 pathology of RA, is not of benefit
in SLE patients. For these reasons SLE has been considered a disease with a Th2 profile,
dominated by antibody-mediated responses [35]. However, the question is not whether we
are dealing with a Th1 or Th2 pathology, but rather whether and how Th1 and Th2
pathologies are involved consecutively or simultaneously in the course of SLE as well as
other immune complex-mediated disorders.
Causes of autoimmunity
Autoimmune diseases are caused by multiple genetic factors with unknown modes of in-
heritance that interact with multiple environmental or stochastic factors. No particular ge-
netic or environmental factor is sufficient or necessary to generate disease. Moreover, the
mutual interaction between the various factors is extremely complex and unpredictable.
Thus the predictive value of any one predisposing mechanism may vary from one patient
to another and from one disease to another.
Genetic predisposition
The important role of genetics is clearly demonstrated by epidemiological studies. The re-
currence of autoimmune diseases within families and the concordance rate of disease in
monozygotic twins indicate a substantial contribution of the shared genetic inheritance in
the development of the disorder. A study on 13,299 pairs of twins in Finland, for example,
showed a 12% concordance rate for RA in monozygotic twins compared with a 4% con-
cordance rate in dizygotic twins [36]. These results assume even more significance if we
consider that the background disease prevalence in nonrelatives was approximately 1%.
Inheritance of susceptibility is generated by the effect of multiple genes which encode
fundamental immune system molecules. A series of linkage analyses have been performed
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over a period of over 10 years to identify the specific alleles involved. Unfortunately, giv-
en the extensive genetic heterogeneity and epistatic interactions among multiple genes it
has often been difficult to interpret the results obtained. Moreover, the immune system
genes identified are not specific for a given autoimmune disorder and affect susceptibility
to many different forms of autoimmunity. It is common in clinical practice to encounter
the coexistence of more than one autoimmune disease within the same family, for exam-
ple, a mother with Hashimoto’s thyroiditis and a daughter with SLE.
MHC genes
The genes of the MHC, located on chromosome 6, are highly polymorphic and seem to
play a central role in generating susceptibility to different autoimmune disorders. Predis-
position to RA, for example, is clearly linked to the presence of the HLA-DR4 genotype,
which is found in approximately 70% of white rheumatoid patients, compared to 28% of
nonrheumatoid patients, conferring a relative risk for the individual of 3.5 [37]. These data
have not been confirmed in other ethnic groups such as native Americans, in whom sus-
ceptibility to the disease seems to be correlated with the HLA-DR9 genotype. Among the
different HLA-DR4 subtypes the ones associated with the disease are Dw4 and Dw14, en-
coded by the DRB1*0401 and the DRB1*0404 alleles, respectively. These genes contain a
specific sequence called “shared epitope,” which is also present in other RA-associated
HLA haplotypes such as DR1, DR6, and DR10, while it is absent in the MCH alleles not
associated with RA. The “shared epitope” encodes for a specific amino acid motif situated
between amino acid 70 and 74 of the class II MHC b1 chain and constitutes an important
binding site for the processed antigen and for the TCR. Therefore this region may be di-
rectly implicated in the pathogenesis of RA [38].
Linkage analysis studies regarding class II MHC alleles have also been performed in
several other autoimmune disorders such as SLE, juvenile RA, and SjÛgren’s syndrome
with less definite results. Class I MHC molecules have also been associated with autoim-
mune disorders. The best characterized is HLA-B27. The associated diseases, character-
ized by the involvement of the spine as a major target of inflammation, are ankylosing
spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease with
spondylitis. The strongest HLA-B27 association is with ankylosing spondylitis, and the al-
lele can be found in about 95% of the patients, independently of ethnic origin. The direct
involvement of the HLA-B27 molecule in the pathogenesis of these diseases is highly
probable [39].
HLA-B51 is a class I MHC molecule strongly associated with BehÌet’s syndrome (BS)
in patients from the Mediterranean Basin, while this association is not found in other geo-
graphical areas. These data underline another important point: for a single disease there
may be different predisposing susceptibility alleles in the different ethnic groups [40].
Genetic background not only predisposes to disease but also influences the severity of
its clinical expression. In RA, a mild disease course with late or absent erosions and good
control with nonaggressive treatment is associated preferentially with HLA-DRB1*01 or
with non-RA linked haplotypes. Conversely, early progressive and destructive disease re-
fractory to common therapy is more frequently found in HLA-DRB1*04 patients [41].
Various hypotheses concerning the mechanisms by which the molecules encoded by
the MHC genes may lead to an autoimmune response have been proposed. (a) The first
focuses on the role of the MHC molecules in shaping the individual antigen-specific T cell
S14
repertoire during thymus ontogenesis. The presence of a particular haplotype may lead,
through positive and negative selection processes, to the final survival of autoreactive T
lymphocytes, thus predisposing to a future disruption of immunological tolerance. (b) The
second hypothesis focuses on MHC molecules as key structures in the selection and pre-
sentation of peptides to T lymphocytes by APC during immune responses. The size, shape,
and biochemical properties of the peptide cleft located at the distal end of the MHC mole-
cules effectively enhance or restrict selection of antigenic epitopes which must be present-
ed to autoreactive T cells in the APC groove. In animal models mutation experiments that
alter the amino acid sequence of this distal end of the MHC peptide have indeed been
shown to have an impact on the selection of antigenic epitopes and their presentation to
autoreactive T cells. (c) The third hypothesis identifies the MHC molecule itself with the
recognized autoantigen. Break of tolerance would occur as a consequence of the resem-
blance (molecular mimicry) between amino acid sequences of the HLA molecule and anti-
genic peptides derived from infectious agents. The normal defensive immune response
against exogenous peptides would thus turn into an autoimmune response to self-HLA de-
terminants.
The fact that autoimmunity-associated MHC haplotypes are also found with high fre-
quency in individuals who never develop an autoimmune disease reinforces again the con-
cept that several genetic loci are involved, and that environmental factors certainly play an
important role.
Complement
The complement system belongs to the innate immune system and is made up of more
than 30 serum and membrane components mediating a multifaceted array of functions.
The most important are chemotaxis and activation of leukocytes, opsonization and phago-
cytosis by polymorphonuclear leukocytes and macrophages, B cell activation, and clear-
ance of immune complexes and apoptotic cells.
Inherited abnormalities in complement factors and complement receptors have been de-
scribed in SLE, RA with vasculitis, mixed cryoglobulinemia, and other systemic vasculi-
tis. Among these diseases, the association between complement deficiencies and lupus is
the best characterized and mainly involves the C4, C1q, and C2 components [42]. In gen-
eral, homozygosis of the defective alleles is rarely seen but confers a higher susceptibility
than heterozygosis. C4 homozygous deficiency requires the absence of a functional gene
product from both of the C4 genes, C4A and C4B. Indeed, when it occurs, 75% of patients
are affected. Conversely, heterozygosity of the C4A null allele is much more common,
and it may not only increase susceptibility to SLE but also influence its severity of expres-
sion. Of note, the C4A null allele is in strong linkage disequilibrium with HLA-DR3, a
class II MHC haplotype associated with the disease, since they are both located in the p21
region of chromosome 6. The importance of the C4A gene product resides in its efficiency
in forming links with amino groups particularly relevant for solubilization and opsoniza-
tion of immune complexes. C2 homozygotic deficiency accounts for a relative risk of de-
veloping SLE of 3.5, and it has been associated with prominent cutaneous manifestations,
while C1q homozygotic deficiency is correlated with severe glomerulonephritis and typi-
cal autoantibodies.
Several hypotheses have been proposed to explain the role of genetic complement defi-
ciencies in the pathogenesis of lupus. The hypothesis focusing on the role of complement
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in the solubilization and clearance of immune complexes and apoptotic waste material
from tissue and circulation is the most accepted. Marked impairment of this function may
result in a cascade of events that ultimately lead to inflammation and tissue destruction
[43].
Other genes
Considerable effort has been devoted to identifying other genes capable of predisposing to
autoimmune disorders. Results are controversial for most of them. Immunoglobulin genes,
TCR genes, cytokine genes, genes involved in apoptosis (e.g., Fas/Fas ligand and bcl-2)
have all been considered. Further studies are needed to establish more definite associa-
tions.
Viruses and bacteria
The role of infection in the development of autoimmunity has been extensively studied
over the years but without any final conclusion being reached. Clinical experience sug-
gests a causal linkage since it is common to detect an infectious episode preceding or ac-
companying the burst of an autoimmune disease in genetically susceptible patients.
Tremendous effort has been put into identifying a viral or bacterial agent that could play a
causal role. Unfortunately, to date only few examples of a clear association between infec-
tious agents and autoimmune disorders have been found. Moreover, the mechanisms by
which they may initiate the autoimmune process are still under debate. The various theo-
ries that have been proposed are based upon the assumption that the host who develops an
autoimmune disease possesses autoreactive lymphocytes which have escaped the mecha-
nisms of central and peripheral tolerance by avoiding deletion in the thymus and in the pe-
ripheral immune system. The activation and subsequent proliferation of these cells by dif-
ferent triggering mechanisms would lead to the disease [44].
1. Molecular mimicry is the most popular hypothesis. Microbial antigens which share
homologies with host antigens drive the initial immune response directed against the in-
fectious agent to an autoimmune reaction against the immunological similar self-peptides.
Cross-reaction may involve linear or conformational epitopes so that there is no need for
an exact amino acid sequence correspondence between self and environmental peptides.
Cellular and/or humoral responses may be involved, and once the autoimmune reaction
has been triggered, microbial antigens may or may not still be present.
2. In the bystander activation model the activation of autoreactive T cells, specific for
an autoantigen X, occurs during an immune response, triggered, for example, by a viral
infection, against the antigen Y. The inflammation generated by the infection may, by tis-
sue destruction, uncover previously sequestered (cryptic) autoantigens which are then pre-
sented to quiescent autoreactive T cells with their consequent activation. Alternatively or
concomitantly, inflammation may create an appropriate local milieu in which upregulation
of MCH molecule expression on APC and promotion of cytokine secretion favors the acti-
vation of “bystander” autoreactive T cells.
3. Superantigens are peptides produced by various pathogens and are characterized by
the ability to activate T cells by binding to the T cell receptor and the MHC outside the
peptide-binding groove. Therefore they are not MHC restricted, do not undergo peptide
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APC processing, and do not rely on specific T cell recognition since they bind to nonpoly-
morphic variable T cell Vb chains. Superantigens, which usually recognize more than one
Vb, can therefore activate up to 100,000 times more T cells than those activated by specif-
ic peptide recognition. Consequently during infection it is possible that among the polyclo-
nal T cells superantigens also activate the autoreactive ones, thus breaking immunological
tolerance. This theory has been proposed for various autoimmune diseases, including RA
and MS.
The complex issue of whether an infectious agent is able to trigger an autoimmune dis-
ease is further complicated in some cases by the difficulty of differentiating between a vi-
ral disease with autoimmune features and a truly autoimmune disease triggered by a virus.
Autoimmune hepatitis (AIH), for example, has been associated with hepatitis C virus
(HCV) following the discovery of a high prevalence of anti-HCV antibodies in patients
with anti-liver-kidney microsomal (LKM) 1 autoantibodies, which are associated with
type 2 AIH. Moreover, molecular mimicry has been proposed between the HCV genome
and cytochrome P450 2D6, which is the major epitope recognized by anti-LKM-1 antibod-
ies. However, not all patients suffering from AIH have anti-HCV antibodies and clinical
and serological differences seem to exist between this group of patients and those who
have encountered the virus (e.g., age, sex prevalence, anti-LKM antibody titer). Thus,
whether this group of patients has an AIH triggered initially by HCV or an HCV hepatitis
with autoimmune features remains controversial. Indeed, the answer may have clinical rel-
evance since “pure” AIH may respond to immunosuppressive treatment and may be exac-
erbated by IFN-a therapy, while virus-associated autoimmunity may benefit from IFN-as-
sociated antiviral treatment [44].
HCV has also been associated with other autoimmune diseases such as type II mixed
cryoglobulinemia, a multifaceted vasculitic disorder characterized by the presence of
monoclonal IgM antibodies with RF activity that precipitate IgG at cold temperatures and
redissolve on rewarming. The majority of patients are positive for anti-HCV antibodies,
HCV RNA, and HCV core proteins. The virus is thought to be responsible for the produc-
tion of RF and other autoantibodies by B cell activation, formation of immune complexes
responsible for vasculitic manifestations (as demonstrated by the presence of HCV RNA
in the lesions and in the cryoprecipitate), and the generation of the lymphoproliferative
disorders associated with the disease by chronic stimulus of B cell expansion. Moreover,
the pathogenetic importance of the virus is also demonstrated by the clinical response ob-
tained with agents that inhibit viral replication and by the fact that remission of vasculitic
lesions parallels the disappearance of HVC RNA in the cryoprecipitate [45].
HCV has been associated with other autoimmune diseases such as autoimmune thyroi-
ditis, RA and sicca syndrome, but in these cases the data seem to be of less certain signifi-
cance. The role of Epstein-Barr virus (EBV) as an initial triggering agent in autoimmune
diseases has been investigated in RA and SLE, and recently an interesting work has shown
evidence of cross-reactive responses between self-HLA epitopes and EBV proteins in ju-
venile RA. Healthy subjects showed cytotoxic responses to EBV derived peptides and not
to homologous sequences of self-HLA-derived peptides while juvenile RA patients re-
sponded to both. The authors hypothesized that molecular mimicry is responsible for the
conversion from a normally self-limited response to EBV infection to a perpetuating auto-
immune response in juvenile RA patients with class II self-MHC molecules serving as au-
toantigens in a disease- and allele-specific manner [46]. Proteus mirabilis has been linked
to RA because of homologous sequences between hemolysin and the “shared epitope” of
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the class II MHC molecule which is responsible for the genetic susceptibility to the dis-
ease. Antibodies against the bacterial enzyme and against the self-HLA peptides have been
detected in patients. In ankylosing spondylitis amino acid sequence mimicry between
HLA-B27 and Klebsiella pneumoniae nitrogenase reductase and pullunanase enzymes has
been investigated [47]. These are merely a few examples among the myriad reports on this
subject. Taken together, the data published so far certainly support a role for viruses and
bacteria in the pathogenesis of autoimmune disorders. Further studies are warranted to bet-
ter elucidate the pathogenetic mechanisms involved and whether there is a specificity of
events for a single micro-organism and in a single disease.
Autoantigens
Autoantigens are a crucial issue in autoimmune disease pathogenesis. Several studies have
been carried out to identify the sequences and the molecules against which the immune
response is directed. The main question is whether the autoantigens identified so far are
really involved in the initiation of autoimmune reactions or are only a secondary phenom-
enon. However, they will certainly help us to better understand the immunological pro-
cesses involved. We discuss below some of the possible mechanisms [48].
Sequestered autoantigens
This theory is based upon the presence of sites such as the eye and testis in which autoanti-
gens are hidden from the immune system by anatomical barriers. Therefore during the de-
velopment of tolerance against self-molecules (e.g., negative selection of T cells in the
thymus), the unavailability of these antigens would prevent deletion or anergy of the spe-
cific autoreactive cells. Following tissue damage the previously sequestered antigens
would be released and the immune system would react against them as it would with for-
eign substances encountered for the first time. Orchitis after vasectomy and sympathetic
ophthalmia after eye injury are two examples of organ-specific autoimmune disorders
which are thought to be generated through these mechanisms.
Cryptic autoantigens
Another interesting theory relates autoimmunity to the release of antigens “sequestered”
within a molecule rather than behind anatomical barriers. Every protein is thought to have
a limited number of dominant determinants against which tolerance develops. “Hidden in-
side the molecule” there are a number of subdominant/cryptic antigens which do not nor-
mally induce immune responses. Thus a sort of hierarchy in the immunogenicity of deter-
minants within a molecule seems to exist. Infectious micro-organisms or other noxious
agents may initiate autoimmune responses by stimulating the presentation of these cryptic
determinants either by molecular mimicry mechanisms or by cytokine-induced upregula-
tion of MHC molecules on APC. Moreover, a response to a cryptic antigen may induce
additional responses to other determinants within the same molecule or in other molecules
by a phenomenon named “epitope spreading,” thus amplifying the autoimmune reaction.
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Modified autoantigens
Another potential source of autoantigens is posttranslational modification of self-proteins
during several physiological and pathological processes. The “remnant epitopes generate
autoimmunity” model focuses on the proteolysis of local proteins occurring during acute
inflammation by extracellular proteinases. According to this theory, the resulting cleaved
peptides (remnant epitopes) are presented to T cells by APC generating autoimmune re-
sponses. In RA, for example, neutrophils attracted into the synovium during the active
phases of the disease produce matrix metalloproteinases able to degrade the extracellular
matrix. The cleavage of local proteins would generate neo-autoantigens. Among matrix
metalloproteinases, gelatinase B, which is increased in the joints of RA patients, cleaves
type II collagen in specific sites with the subsequent release of immunodominant epitopes.
Gelatinase B is also increased in the cerebrospinal fluid of MS patients and cleaves human
myelin basic protein into immunodominant peptides recognized by the immune system
[49].
Proteolysis and several other posttranslational modifications of self-molecules occur
during apoptosis, as explained in detail below.
Apoptosis
Apoptosis is a form of cell death which occurs in several physiological processes to con-
trol excessive cell proliferation and to eliminate damaged or unwanted cells. Therefore it
is involved in limitation of immune responses after successful infection control, deletion
of self-reactive T and B lymphocytes during central and peripheral tolerance processes,
regulation of cell proliferation during embryogenesis, and tissue healing. Apoptosis can be
triggered by various noxious stimuli or by a deficit of survival signals and consists of a
multistep process in which the apoptotic cell goes through morphological and biochemical
changes. Clearance of dying cells is rapidly performed through engulfment phagocytosis
by macrophages and semiprofessional phagocytes (e.g., kidney mesangial cells) and is not
associated with release of proinflammatory mediators.
Dysregulation of apoptosis is thought to play an important role in the generation of au-
toimmunity by different mechanisms, as demonstrated by experimental evidence:
1. Mutations of genes involved in the induction of apoptosis (Fas and Fas ligand) result
in a rare autoimmune-lymphoproliferative disorder termed Canale-Smith syndrome and
characterized by an alteration in lymphocyte survival. Patients with this syndrome present
an abnormal elevation in undifferentiated “double negative T cells,” chronic lymphaden-
opathy, splenomegaly and various manifestations of autoimmunity such as hemolytic ane-
mia and thrombocytopenia [50].
2. During cell apoptosis many intracellular autoantigens such as nucleosomal DNA,
Ro, La, U1-snRNP, and other molecules recognized by autoantibodies in autoimmune dis-
eases are relocalized and clustered on the cell surface in apoptotic blebs and bodies, be-
coming available for recognition by autoantibodies. Moreover, these molecules go through
posttranslational modifications by caspase cleavage, deubiquitination, phosphorylation,
transglutamination, and other as yet unidentified pathways, with potential creation of
neoepitopes to which T and B cells have not been rendered tolerant [51].
3. Defective clearance of apoptotic cells has been found in patients with SLE. This may
be due to overabundant apoptotic material which exceeds the phagocytic capacity of the
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reticuloendothelial system (e.g., after ultraviolet exposure or infection) or to intrinsic de-
fects in the mechanisms of engulfment phagocytosis. The latter may be associated, for ex-
ample, with C1q complement deficiency since C1q acts as an opsonizing receptor favoring
phagocytosis. Abnormal accumulation of apoptotic cells may represent a continuous
source of highly concentrated and altered autoantigenic material [52].
4. Moreover, the unremoved cells may enter other dying processes such as secondary
necrosis, which leads to the further generation of neoepitopes through new proteolytic pro-
cesses which stimulate proinflammatory removal pathways that create an appropriate mi-
lieu for the development of autoimmune responses (e.g., release of cytokines and chemo-
kines, expression of costimulatory signals, activation of DC, exposure of adhesion mole-
cules) [53].
The cited mechanisms may not be mutually exclusive and probably interact in a multi-
factorial manner.
Triggering factors
There are several agents which are thought to have an impact on the course and exacerba-
tion of autoimmune diseases. This issue is of major importance since patients often won-
der whether changes in their life-style would contribute to a better management of their
illness. Intercurrent infections, psychic and physical stress, diet, ultraviolet radiation, hor-
mones, and cigarette smoking are among the triggering factors that have gained increasing
scientific attention.
Intercurrent infections
We discuss above the potential role of viruses and bacteria in the development of autoim-
mune disorders and stress that to date no conclusive data have been presented definitely
implicating a specific micro-organism. Another interesting issue is the effect that ubiqui-
tous infectious agents determining common intercurrent infections may have on the course
of the disease. It is not uncommon to encounter relapse of an autoimmune disease follow-
ing upper respiratory or gastrointestinal infections. In this respect some autoimmune dis-
eases are more susceptible than others. Berger’s nephropathy with macroscopic hematuria,
for example, often follows tonsillitis. Studies have suggested that stimulation of the mu-
cosal immune system by infection leads to an increased IgA production and formation of
immune complexes responsible for renal damage [54]. Other studies have proposed Gram-
negative bacterial lipopolysaccharide, which is a polyclonal B cell activator and IL-1 and
TNF-a synthesis inducer, as another potential trigger for the reactivation of autoimmune
responses, especially in some autoimmune disorders such as Crohn’s disease [55].
Stress
It is generally accepted that stress can influence immune responses. Clinicians can fre-
quently trace a stressful event preceding the burst of an autoimmune disease or altering its
course by aggravating or precipitating a flare. Several studies conducted on this issue have
associated disease onset and relapse to specific events such as marriage or divorce, moving
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house, pregnancy, business loss, and physical traumatic events such as a surgical interven-
tion. Stress can also be generated by the illness itself. Patients affected by an autoimmune
disease have to accept the fact that they suffer from a chronic illness, that they need to be
under treatment and to face periodic laboratory and clinical controls throughout their life-
time, and that they must learn to cope with potential disability. Patients unable to cope
emotionally with their disease often present a worst prognosis with poorer response to
treatment [56]. The exact mechanisms by which stress influences the immune system are
not fully understood. The organic reaction to stress involves peptide hormones, some of
which, such as b-endorphin and substance P, have immunoregulatory properties and might
be expected to modulate inflammatory reactions. Moreover, stress has been associated
with a decreased immune lymphocyte responsiveness. Unfortunately, the intangible nature
of stress often renders difficult the investigation, in controlled experimental trials, of its
multiple consequences in immune processes.
Diet
The role of diet in influencing immune system function has long been a matter of debate.
Most of the available studies come from autoimmune disease animal models and seem to
support the hypothesis that moderate calorie restriction and low protein and fat intake can
decrease morbidity and mortality. Beneficial effects of polyunsaturated fatty acids such as
w-3 fatty acid fish oil and linseed oil are well established. Results of studies on SLE and
RA patients show serological and clinical improvement with a diet that is enriched in
polyunsaturated fatty acids. Underlying mechanisms of action seem to involve modulation
of inflammatory eicosanoids and cytokine levels. Moreover, w-3 fatty acids appear to up-
regulate apoptosis of autoreactive T lymphocyte precursors in the thymus [57]. Other pos-
sible beneficial dietary compounds include vitamin E, vitamin A, and selenium [58].
Ultraviolet radiation
Sun exposure does not have the same effect on all autoimmune diseases. On some it has a
detrimental effect, on others a beneficial one, but in the majority it does not seem to affect
the disease course. Photosensitivity is part of the major diagnostic criteria in SLE, and ul-
traviolet radiation is able to induce cutaneous and visceral flares. Extensive work has been
performed by researchers to determine the underlying mechanisms. It has been demonstra-
ted that ultraviolet light induces apoptosis of keratinocytes. As a consequence of this sev-
eral intracellular lupus autoantigens such as Ro, La, snRNP, and Sm, are modified and ex-
posed on the dying cell surface and become available to be recognized by autoantibodies
[59]. In addition to autoantigen overexpression, other immunological abnormalities might
be involved in the formation of SLE cutaneous lesions. In fact, repeated or persistent ultra-
violet exposure initiates a cascade of proinflammatory events in the epidermis and the der-
mis, with the release of IL-1, TNF-a and several other chemokines and cytokines which
create the appropriate milieu for adhesion molecule induction, activation and migration of
leukocytes, initiation of immune responses, and production of autoantibodies. In this con-
text, dermal inflammation is followed by epidermal cytolysis through T cell cytotoxicity,
antibody-dependent cell-mediated cytotoxicity, direct cytokine effects, and complement-
mediated lysis [60]. Conversely, daily sun exposure has beneficial effects on another auto-
immune disease, psoriasis. Ultraviolet radiation treatment significantly reduces the Psoria-
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sis Area and Severity Index score, and interesting work has demonstrated that ultraviolet
A plus methoxypsoralen induces a shift from a Th1 to a Th2 cytokine response [61]. This
is particularly important since psoriasis is a Th1 cell driven disease, and changes in cyto-
kine production may influence disease activity.
Cigarette smoking
There is increasing evidence that cigarette smoking is an important risk factor affecting
the incidence and severity of many autoimmune diseases such as systemic sclerosis, RA,
lupus nephritis, Graves’ disease, and Goodpasture’s syndrome. RA smokers, for example,
tend to have higher levels of RFs, worse Larsen scores on radiography, worse functional
disability, and an increased incidence of extra-articular manifestations such as rheumatoid
nodules, interstitial lung disease, and vasculitis, probably partly mediated by a direct effect
of smoke on blood vessels and angiogenesis [62]. Smoke has various effects on the im-
mune system: it produces abnormalities in T lymphocyte function, reduces natural killer
cells, depresses humoral and cell-mediated immunity, and inhibits prostaglandin synthesis.
It also has direct effects on the endothelium, promoting leukocyte and platelet adhesion to
endothelial cells and impairment of endothelial cell-dependent vasodilatation by alteration
in nitric oxide biosynthesis and action. Furthermore, cigarette smoke produces several tox-
ic components, including reactive oxygen and nitrogen species that cause oxidative and
nitrosative stress, a phenomenon directly implicated in the pathogenesis of some autoim-
mune diseases such as systemic sclerosis and Raynaud’s disease [63].
Hormones
An effect of sexual hormones on the development and course of autoimmune diseases is
suggested by various clinical evidence. Many autoimmune disorders, for example, display
an unbalanced sex ratio prevalence, the majority showing a definite preponderance of
women; in SLE the female to male ratio is 9:1, in RA 4:1, and in systemic sclerosis 3:1,
although in the younger age group it may reach 7:1. Conversely, ankylosing spondylitis
shows a sex predilection for men of 5:1 or higher, while gender does not seem to affect
the incidence of Wegener’s granulomatosis, a systemic autoimmune vasculitis with a sex
ratio of 1:1. Physiological hormonal fluctuations occurring during life also seem to influ-
ence the development of some autoimmune disorders (e.g., SLE onset occurs mostly dur-
ing women’s fertile years, relatively sparing prepuberty and postmenopausal periods).
Moreover, pregnancy and the postpartum period are the times of highest risk for variations
in the disease course (e.g., RA tends to ameliorate during pregnancy and relapse during
postpartum), imposing a higher frequency of laboratory and clinical controls on patients
and an appropriate adaptation of treatment.
The mechanisms by which sexual hormones affect disease development and activity
are not fully understood. In vitro experiments suggest that estrogens stimulate humoral im-
munity, inducing differentiation and activation of B cells, promoting the production of au-
toantibodies, and increasing Th2 cytokine production. Moreover, the effects of estrogen
administration and androgen deficiency in murine models of SLE confirm the important
role of these hormones in modulating disease expression and prognosis. The effect of ex-
ogenous estrogens has not been studied in all autoimmune disorders, but recent reports in-
dicate a certain safety of their use in selected patients [64]. The issue is of major impor-
S22
tance when considering its use for oral contraception, particularly important during terato-
gen treatment and to control cyclic hormonal diseases, and its employment as hormone re-
placement therapy in the postmenopausal period mainly to preserve bone mineral density
and prevent cardiovascular diseases. Most available data come from studies in SLE, where
recent studies have not confirmed the early retrospective studies which linked the adminis-
tration of exogenous estrogens with an increased risk of flares. The issue remains contro-
versial, although the current trend is to allow combination low-dose estrogen-progesterone
oral contraceptives in SLE patients in the absence of major organ involvement, such as in
active lupus nephritis, and in the absence of anticardiolipin antibodies which carry a high-
er risk of thromboembolic complications. On the other hand, hormone replacement thera-
py after menopause, which utilizes naturally conjugated equine estrogens with a much
lower estrogenic potency, does not seem to increase lupus activity, and preliminary data
from a large multicenter, double-blind, placebo-controlled trial (the Safety of Estrogens in
Lupus Erythematosus-National Assessment study) suggest significant health benefits for
these patients [65]. Hormone replacement therapy has also been reported to be safe for RA
[66].
Drugs used in the treatment of autoimmune diseases
Autoimmune diseases comprise a multitude of conditions involving both disease-specific
and non-disease-specific genetic factors and a plethora of disease-triggering and disease-
modifying environmental factors, varying from patient to patient and variable during the
course of the disease. Further complicating the situation is the fact that response to drugs
often varies from patient to patient. The latter complication is due in part to pharmacoge-
netics and in part to environmental factors, including alcohol consumption and tobacco.
Thus, one patient with RA may respond well to methotrexate (MTX) but not to lefluno-
mide (Lef) while another responds to Lef but not to MTX. Faced with such a “protean”
clinical pathology which differs from patient to patient and is variable over time, one can-
not expect a rigid treatment regimen to be effective in autoimmune diseases. Rather, such
conditions require an almost custom-made approach, with treatment tailored according to
variations in disease activity. This is possible only with the patient’s active participation.
Treatment must be a “joint-venture” and will be a long partnership between patient and
physician since most autoimmune diseases tend to have a very chronic course. The prima-
ry aim of treatment is long-term disease control with a good quality of life and minimum
drug toxicity.
Fifty years ago, the range of drugs available to the physician for treating autoimmune
diseases was very limited, cortisone being the only efficient drug. The number of im-
munomodulating compounds has gradually increased and today there are more than 20 dif-
ferent agents. This development now permits the clinician to administer individually tai-
lored treatment, combining drugs with different mechanisms of action in an attempt to in-
crease the overall therapeutic efficacy without concomitant increase in global toxicity.
Corticosteroids
Glucocorticosteroids were long the cornerstone of immunosuppressive treatment. Howev-
er, side effects, particularly in patients on long-term medication, greatly outweighed the
S23
beneficial effects. These side effects include Cushing’s syndrome, osteoporosis and aseptic
bone necrosis, cataract formation, increased susceptibility to infections, linear growth ar-
rest in children, and suppression of the hypothalamo-pituitary-adrenal axis leading to cor-
ticodependence. To maintain a tolerable level of side effects oral long-acting steroids
should be avoided. Short-acting steroids (prednisone, Pred; fluocortolone) given no more
than 5 days per week do not suppress the hypothalamo-pituitary-adrenal axis [67]. In chil-
dren three steroid-free days per week (e.g., Tuesday, Thursday, Sunday) are necessary to
permit normal linear growth. In acute situations intravenous pulse therapy has been shown
to be more efficacious (125 mg methylprednisolone, MP, or 40 mg dexamethasone, DXM)
than daily oral administration of high doses of cortisone. Oral steroids should be adminis-
tered in a single morning dose.
6-Mercaptopurine
6-Mercaptopurine (6-MP) has now been in use for over 40 years for the treatment of pa-
tients suffering from autoimmune diseases. Azathioprine (AZA), an imidazole–6-MP com-
pound, was developed with the aim of only slowly releasing the active part, 6 -MP, in the
liver. Some patients tolerate AZA (100 mg/day) better while others tolerate 6-MP (50 mg/
day) better, especially in the case of liver involvement. Toxicity, very variable from pa-
tient to patient, involves the bone marrow and the gastrointestinal tract. Given daily for
long periods, the drug becomes less efficient, probably because of metabolic adjustment.
These patients may finally tolerate doses of 6-MP (e.g., 150 mg/day) which would produce
bone marrow depression if given as an initial dose in previously untreated patients. Not
only the immunosuppressive activity, but also the myelotoxicity diminishes with time.
This loss of activity can be avoided if AZA or 6-MP is given during alternate weeks or
months.
Methotrexate
In 1963 we investigated the efficacy of the two antimetabolites 6-MP and MTX in treating
experimental autoimmune thyroiditis in guinea pigs [68]. The results of these investiga-
tions showed that these antimetabolites have a therapeutic effect once the disease is al-
ready established. MTX appeared more effective than 6-MP in terms of the toxicity/effica-
cy ratio. In febrile SLE patients 15 mg MTX given intravenously or intramuscularly pro-
duced a rapid normalization of body temperature and clinical improvement for a period of
5–7 days [69]. Oral MTX does not have this dramatic effect. If MTX is given once per
week, late toxicity appears after 6–8 weeks (mucosal irritation/soreness). If protected by
folic acid (5 mg on 3 consecutive days after MTX injection) and with at least a 1-week
pause per month, MTX is well tolerated for long periods by most patients.
Cyclophosphamide
Cyclophosphamide (Cy) is a potent lymphocytotoxic alkylating agent that has been used
for many years as an immunosuppressant. It is undoubtedly a very powerful lymphocyto-
toxic agent, but also entails substantial side effects, particularly when administered orally.
After the occurrence of leukemia in 1979 and 1980 in two of our patients on long-term
S24
oral Cy we ceased oral administration of this drug. Since 1980 none of more than 400 pa-
tients on intravenous Cy pulse therapy has developed leukemia or any other malignancy.
Because of its cancerogenicity Cy is administered only as intravenous pulses, in associa-
tion with other immunosuppressive drugs, at a maximum dose of 12 pulses of 500 mg per
year. Adequate hydration is essential to avoid Cy toxicity during intravenous administra-
tion: 1.5–2.0 l tea or water plus 25 mg furosemide to guarantee rapid elimination of Cy
and to avoid irritation of the bladder mucosa.
Cyclosporine A
The introduction of the noncytotoxic immunosuppressive agent cyclosporine A (CsA) in
1982 greatly increased the immunomodulating potential of treatment. CsA forms a com-
plex with cyclophyllin in T lymphocytes which binds to calcineurin, leading to inhibition
of the production of IL-2 and IL-2 receptor. As a consequence secondary B cell functions
are also decreased. Renal toxicity has delayed the general acceptance of CsA which was
initially used in monotherapy with nephrotoxic doses (8–12 mg/kg per day). Fortunately,
in our patients we limited the dose from the very beginning to less than 5 mg/kg per day.
In combination with low doses of cortisone and MTX [70, 71] this dose of CsA showed no
or only insignificant signs of toxicity in 192 kidney biopsy specimens. Furthermore, long-
term medication (15–20 years) did not lead to impairment of kidney function. Today the
daily dose of CsA is kept below 4.5 mg/kg lean bodyweight per day. Abrupt discontinua-
tion of CsA medication is likely to produce a resurgence in disease activity. Accordingly,
CsA doses should be reduced only gradually once the patient is in remission. Side effects
of CsA include hirsutism, gingival hyperplasia, water retention, hypertension, and in-
creased levels of cholesterol and uric acid. Among these side effects gingival hyperplasia
has precluded the use of CsA in 2–3% of our patients, for whom tacrolimus, another cal-
cineurin antagonist, can be used as a substitute for CsA, at a daily dose of 0.1 mg/kg.
Tacrolimus
This macrolide acts as a calcineurin antagonist, similarly to CsA. Its rate-limiting side ef-
fect is nephrotoxicity. Hypertension, alopecia, leukopenia, and neurological disturbances
are dose dependent. For autoimmune diseases the initial daily dose should not exceed
0.15 mg/kg and that in long-term medication 0.1 mg/kg.
Everolimus
A structural analogue of sirolimus, everolimus binds to the cytosolic immunophyllin
FKBP 12. It inhibits growth factor driven cell proliferation at a later stage in the prolifera-
tion process than CsA and tacrolimus. Everolimus can therefore be used in association
with CsA or tacrolimus at a dose of 1 mg twice daily, increasing the immunosuppressive
action without concomitant increase in drug toxicity.
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Mycophenolate mofetil
The active metabolite of mycophenolate mofetil (MM), mycophenolic acid, inhibits the de
novo pathway of purine synthesis in T and B lymphocytes, which rely almost entirely on
this de novo pathway. MM has been reported to be more efficient than 6-MP, but it is also
less well tolerated by patients at the recommended daily dose of 2 g. Side reactions in-
volve the gastrointestinal system, myelotoxicity with neutropenia, and occasionally eleva-
tion of transaminases.
Hydroxychloroquine
Hydroxychloroquine (HCQ) acts on lysosomal activity which inhibits the function of lym-
phocytes and macrophages differently from other immunosuppressive agents. Side effects
are relatively mild. The development of corneal deposits does not affect vision. Retinopa-
thy, mostly observed with the use of chloroquine, rarely occurs with HCQ (for this reason
chloroquine is no longer used as an immunosuppressive drug). Gastrointestinal side effects
are dose dependent.
Leflunomide
Lef inhibits the synthesis of pyrimidine, leading to apoptosis and cell cycle arrest. It af-
fects the synthesis of cytokines by increasing the mRNA level of IL-10. It also has an anti-
inflammatory effect by inhibiting cyclooxygenase-2 activity. Lef is well tolerated by most
patients. In the event of intestinal intolerance Lef should be stopped immediately without
waiting for laboratory results (transaminases). Lef is teratogenic and remains in the system
for a very long time (more than 1 year). Should a patient in remission wish to become
pregnant, Lef can be “washed out” of the tissues with cholestiramide (8 g t.i.d. for
11 days).
d-Penicillamine
d-Penicillamine (DP) was introduced for the treatment of RA on account of its capacity to
break up S-S bridges, thus degrading IgM molecules. However, this effect requires con-
centrations of DP which are unattainable in patients. The immunosuppressive effect of DP
is presumably a consequence of its action on surface receptor sulfhydryl groups of T lym-
phocytes and monocytes. DP was originally used at very high doses (900–1200 mg per
day) which produced excessive side reactions in patients. With drug-combination therapy
a daily dose of 150 mg (at most 300 mg) produces satisfactory results in many patients
with few side effects (gastrointestinal intolerance, diminution of taste).
Thalidomide
Thal was introduced in 1956 as a sedative but was withdrawn 5 years later on account of
its teratogenicity. However, when used to sedate leprosy patients, Thal was shown to pro-
duce a dramatic improvement in erythema nodosum leprosum. In subsequent years Thal
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has been reported to improve various immunopathological conditions such as discoid lu-
pus erythematosus, graft-versus-host disease, and erosive lichen planus. The mechanism
of action in these conditions is not fully understood. Thal appears to have anti-inflammato-
ry and immunosuppressive properties, which become most evident with large, toxic doses
of up to 800 mg/day. More recently Thal has been shown to suppress TNF-a production
and to modify the expression of TNF-a induced adhesion molecules on endothelial cells
and human leukocytes. Another effect involves inhibition of angiogenesis, which could
explain its action on certain tumors. In addition to its sedative and teratogenic effect, an-
other side effect of Thal is peripheral neuropathy, which has become the main rate-limit-
ing factor. Thal is not suitable for monotherapy but is useful in drug-combination therapy
at a daily dose of 50–200 mg (maximum).
Sulfasalazine
Sulfasalazine (SSZ) is split in the colon into sulfapyridine and 5-aminosalicylic acid, ex-
erting a local immunomodulatory and anti-inflammatory action.
FTY 720
FTY 720 is a sphingosid analogue which alters lymphocyte recirculation and homing,
most probably by modulating glycoprotein-coupled receptors on lymphocytes.
Etanercept
Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion
of the human 75-kDa TNF receptor linked to the Fc portion of human IgG1. Administered
as a subcutaneous injection, it has a short median half-life of 115 h, which permits a great
flexibility in the management of autoimmune disease in which TNF plays a relevant role
in the pathogenesis of tissue damage. Etanercept is well tolerated at the recommended
dose of 25 mg, given twice weekly as a subcutaneous injection. As with other TNF block-
ing agents, etanercept increases the risk of infection. A strongly positive Tbc skin test ex-
cludes the use of this drug. In this respect the short median half-life is an advantage, leav-
ing enough time for the action of TNF in the event of intercurrent infections.
Infliximab
Infliximab is a chimeric murine/human monoclonal antibody to human TNF-a, given as a
slow intravenous infusion. With a median half-life of several weeks, infusions of this drug
can be given at intervals of 2–8 weeks (recommended regimen: 3 mg/kg on day 1, a fur-
ther 3 mg/kg 2 weeks and 6 weeks later, subsequently 3 mg/kg every 8 weeks). The long
median half-life of infliximab may be considered as an advantage, but restricts flexibility
in the adjustment of treatment to variations in disease activity. The long half-life also in-
creases susceptibility to infections. In particular, if there are signs of tuberculosis activity,
infliximab is contraindicated. A Tbc skin test should be done before initiating treatment
with infliximab.
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Adalimumab
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human TNF-
a. With a median half-life of 2 weeks it is administered subcutaneously at a dose of 40 mg
every other week. It entails an increased susceptibility to infections, especially tuberculo-
sis. As with other anti-TNF agents, close supervision of patients for intercurrent infection
is necessary. A strongly positive Tbc skin test excludes the use of adalimumab.
Rituximab
Rituximab is a chimeric murine/human monoclonal antibody directed against the CD20
antigen of B lymphocytes. It is administered as a slow intravenous infusion at weekly in-
tervals. Serious side reactions may occur during intravenous infusion. Rituximab may be
useful in remission induction of antibody-mediated immunopathology.
Daclizumab
Daclizumab is a chimeric (90% human, 10% murine) IgG1 monoclonal antibody directed
against the IL-2 receptor that is expressed on activated lymphocytes. It may be useful in a
remission-induction regimen of Th1-mediated autoimmune diseases at a dose of 1 mg/kg
at 14-day intervals, for a total of 4 doses.
Efalizumab
Efalizumab is a humanized monoclonal antibody acting on the adhesion molecule lympho-
cyte function associated antigen 1 (CD11a) which is important for the trafficking of acti-
vated lymphocytes from the circulating blood into tissue. It also interferes with the interac-
tion of activated lymphocytes with APC. Intercellular adhesion molecule 1 serves as li-
gand for lymphocyte function associated antigen 1. This agent has been shown to be effec-
tive for the treatment of psoriasis at a dose of 0.3 mg/kg, given as a weekly infusion over a
7-week period. It may be useful in drug-combination therapy for the prevention of graft
rejection.
Anakinra
Anakinra is a recombinant, nonglycolysated form of the human IL-1 receptor antagonist.
It is well tolerated at daily subcutaneous doses of 1 mg/kg and appears to be efficient in
the treatment of Th1-mediated autoimmune diseases, especially in combination with
MTX. TNF blocking agents should not be used in conjunction with anakinra.
Glatirameracetate
Glatirameracetate is a synthetic polypeptide salt composed of four amino acids in variable
composition (molecular weight: 4.7–10 kDa), simulating degradation products of the basic
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myelin protein. Administered subcutaneously, it is thought to act as a tolerogenic agent in
the treatment of MS.
Colchicine
Colchicine is an alkaloid that acts on microtubular structures, intracellular in the case of
mitotic metaphase, extracellular in cell to cell interaction. It has shown its efficacy in fa-
milial Mediterranean fever, gout, BS, and in certain connective tissue diseases with fever.
It also delays progression of liver cirrhosis in patients with primary biliary cirrhosis
(PBC). Finally, it diminishes the rate of sequestration of autoantibody-coated red cells.
Mitoxantrone
Mitoxantrone is a cytotoxic derivative of anthraquinone. It is occasionally used in the im-
munosuppressive treatment of MS.
Dapsone
Dapsone (diamino-diphenyl sulfone) has been introduced for the treatment of leprosy. As
with Thal, it is active on erythema nodosum leprosum, probably through its immunosup-
pressive activity.
Levamisol
Levamisol has been shown to increase T cell activity in animals with a diminished func-
tion of these cells. Because of this “thymomimetic” activity, levamisol has been used in
patients with RA with remarkable results. Not only did the patients feel better after 2–
3 weeks of treatment (100 mg orally twice per week), with diminished symptoms and
signs of arthritis, but laboratory parameters also improved. Unfortunately, the occurrence
of allergic reactions in over 20% of patients has led to the almost total elimination of this
drug from standard treatment protocols. Research to find drugs with a similar thy-
momimetic function has been unsuccessful so far. Levamisol remains a candidate for early
intervention in selected patients, well informed of the risk of allergic reactions (the most
common being a flulike reaction; agranulocytosis and erythematous skin eruptions occur
in fewer than 2% of patients). If a patient does not develop an allergic reaction after
4 months of treatment, the drug may be continued for long periods (years), at a mainte-
nance dose of 100–150 mg as a single weekly dose in the treatment of RA. A complete
blood count should be performed every 2 weeks during the first 4 months.
Danazol
Danazol inhibits the synthesis of gonadotrophines and increases the production of C1 es-
terase inhibitor. It has proven useful in the management of patients with angioneurotic
edema and to a lesser extent in autoimmune thrombocytopenia.
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Basic strategies of treatment
All autoimmune conditions have in common an ongoing immune response directed to-
wards disease-specific autoantigens, based on a genetic predisposition. They are subject to
many disease-triggering and disease-modifying environmental factors. As in all immune
responses, specific T and B lymphocytes undergo clonal expansion, which is beneficial in
the case of infection, detrimental in autoimmune conditions (see below). APC are equally
involved in both the afferent and efferent pathways of the immune response. Accordingly,
these cells are targeted in all basic therapeutic approaches to autoimmune disorders.
For many decades cortisone was considered to be the most powerful agent for blocking
the pathogenic immune process. However, it gradually became evident that prolonged
treatment with cortisone does not provide lasting cure and also produces adverse events
which increase with time (e.g., Cushingoid changes, fluid retention, hypertension, osteopo-
rosis, linear growth arrest in children). Furthermore, cortisone does not really halt the pro-
gression of the basic disease process. For these reasons steroid monotherapy for very mild
forms of autoimmune disease conditions should be limited to no more than 45 mg Pred
per week.
Today, with more than 20 different immunosuppressive and immunomodulating agents
available, the era of cortisone dominance is over. However, it must be stressed that none
of these drugs used as monotherapy is capable of controlling relevant disease activity. A
combination of drugs, each with a specific target on the immune response but with differ-
ent side reactions, and each administered at a dose below its toxic level, has thus become
the basis of all treatment regimens.
The earlier the pathological immune response is halted, the faster one may expect to
see a therapeutic response. With “symptomatic” treatment only, the autoimmune disease
process is allowed to continue without being recognized as such. This applies not only to
treatment with NSAIDs, but also to steroids. In such situations patients are under the illu-
sion that they are being cured. This is true for all autoimmune disease, but particularly for
RA. Patients with RA do not understand why they should not continue with NSAIDs,
which give them so much relief. As if “anesthetized,” they do not realize that the joint
damage is continuing unhindered. When well informed, they readily accept to limit
NSAIDs to a minimum. However, they expect and request from the physician an effective
intervention with visible results within weeks, not months. Without early intervention the
disease process continues, with progressive clonal expansion of autoaggressive lympho-
cytes rendering immune intervention increasingly difficult.
Adjustment of treatment intensity to disease activity
At diagnosis it is not possible to predict exactly how the disease will evolve. Without early
and appropriate therapy a seemingly “mild” disease process may lead to irreparable tissue
damage. For this reason and in view of the danger of clonal expansion of autoreactive lym-
phocytes, early and vigorous immunosuppression is advisable, with subsequent reduction
in treatment intensity as disease activity diminishes. With the availability of potent immu-
nosuppressive drugs the approach of the past, i.e., low-dose initial treatment slowly in-
creasing in intensity in the case of insufficient response, is now obsolete. Given the choice,
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and recognizing the risk of irreparable damage in the case of insufficiently intense initial
treatment, well-informed patients prefer a more vigorous initial treatment.
General rules of treatment regimens
We summarize here our own experience with drug-combination therapy. The main moti-
vation for combining drugs with different mechanisms of action is the devastating effects
that have been produced by cortisone monotherapy in patients with autoimmune diseases.
This was the reason that we introduced drug-combination therapy for our patients in New
York in the early 1960s, with the limited number of drugs available at that time. Today,
the abundance of potent agents makes it possible to provide effective treatment with a
minimum of drug toxicity. In particular, the risk of cancerogenicity, initially a cause of
concern, has proven to be negligible, in contrast to the situation in transplanted patients
under intensive immunosuppressive treatment.
Controlled studies are important for the objective assessment of drug efficacy. In auto-
immune diseases this approach is problematic since it is almost impossible to set up well-
matched homogeneous patient groups with the great variations in disease expression from
one patient to another. Despite these difficulties, however, positive results obtained in such
studies have been valuable in the assessment of drug efficacy. However, a negative result
does not necessarily exclude a drug which has been shown to have immunosuppressive
properties.
Once a drug has been well defined with regard to its mechanism of action in the im-
mune response, with positive results in animal models and in clinical studies including the
prevention of graft rejection, its clinical application should not be limited to a specific au-
toimmune disease. It should be realized that a drug which is efficacious for one autoim-
mune disease is in general also effective in other, clinically very different, autoimmune
diseases. In other words, the clinician must recognize that the same basic immunopatho-
logical mechanisms are common to more than 40 different autoimmune disease entities.
Treatment must be aimed at the underlying autoimmune process.
T and B lymphocytes and APC are similarly involved in all autoimmune conditions.
Differences in the response to treatment depend on whether cellular or humoral factors
prevail, as well as on the specific organ or tissue involvement of the disease process.
Treatment regimens can be oriented on the basis of these differences. However, it is not
possible to set up long-term rigid treatment protocols in view of the great variability in
disease expression both from one patient to another and during the course of the disease.
Thus, physicians should be aware of the need for flexibility and readiness to change treat-
ment should unforeseen events alter the expression of the disease.
Remission-induction regimens and maintenance therapy
Untreated, autoimmune diseases are severe and potentially deadly conditions, and by their
nature (genetic predisposition) they tend to be chronic. The enormous progress in diagno-
sis as well as the great improvement in treatment modalities over the past 50 years has
changed the outlook and quality of life for patients affected by an autoimmune disease.
Once remission has been achieved, if unaware of the potential chronicity of these condi-
tions, the patient and physician may be tempted to discontinue immunosuppressive treat-
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ment altogether. However, such an approach entails a great risk of disease recurrence. For
this reason patients must be informed at the beginning that treatment may have to continue
for a long time, frequently for years.
The protocols outlined below differentiate between those for remission-induction thera-
py (R-Th) and those for maintenance therapy (M-Th).
Patients with low initial disease activity
Protocol:
– R-Th1
– The combination of Pred, CsA, MTX, and AZA is well tolerated by most patients
and permits rapid control of disease activity. Treatment may be initiated with a sin-
gle i.v. injection of 15 mg MTX + 80 mg MP, followed by:
– Pred: 10 mg, 5 per week for 4 weeks, subsequently 4 per week.
– MTX: 15 mg per week in a single i.m. or i.v. injection for 4 weeks, subsequently
every other week.
– Folic acid: 5 mg per day for 3 days after MTX.
– AZA: 100 mg per day, 6 days per week during MTX-free weeks.
– ASA: 100 mg every evening
Once the disease is well controlled, Pred should be gradually reduced until reaching a
weekly dose of 20 mg (45 mg). MTX may then be given orally at a dose of 10 mg per
week during alternate weeks, reaching maintenance therapy M-Th1 (see below). Protocol:
– M-Th1
– Pred: 5 mg, 4 per week.
– MTX: 10 mg/wk p.o., given on 3 nonconsecutive days, every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– AZA: 100 mg per day, 6 days per week during MTX-free weeks.
– ASA: 100 mg every evening.
Patients with high initial disease activity and normal creatinine levels
The cortisone effect in these patients can be maximized without significant increase in ste-
roid toxicity by administering intravenous pulses of 125 mg MP or 40 mg DXM. These
intravenous pulses may be continued on days 2, 4, and 6. In the case of very severe disease
activity additional MP pulses may be necessary (MP produces fewer steroid side effects
than DXM because of its short half-life: 3 h vs. 24 h for DXM). The therapeutic cortisone
effect is increased during the first week because of the long half-life of DXM. After the
initial intravenous steroid pulses Pred is continued orally together with CsA, MTX, and
AZA. Protocol:
– R-Th2
– Initiation of treatment with i.v. steroid pulses (see above), followed by:
– Pred: 10 mg, 5 per week for the first month, subsequently 4 per week.
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– CsA: 4.5 mg/kg per day (lean bodyweight) in two daily doses, 6 days per week.
– MTX: 15 mg in weekly i.m. injections for 1 month, subsequently every other week.
– Folic acid: 5 mg per day for 3 days after MTX.
– AZA: 100 mg per day, 6 days per week, during MTX-free weeks.
– ASA: 100 mg every evening
– If disease is not brought under control with the combination of Pred, CsA, MTX,
and AZA: Cy 500 mg + MP 125 mg in 15-min perfusion with adequate hydration,
once in a 4-week period during an MTX-free week.
Once a patient is in remission, treatment intensity should be gradually reduced. Obvi-
ously the drugs with the greatest toxicity potential should be the first to be diminished,
particularly Cy: either the number of Cy pulses should be reduced, or Cy completely
stopped. Steroid toxicity is always underestimated; 3 steroid-free days should be intro-
duced as soon as possible. CsA doses should be gradually tapered once the disease process
has been under control for at least 5 months, either reducing the daily dose or increasing
CsA-free days. Rapid discontinuation of CsA entails the risk of relapse (“rebound phe-
nomenon”).
Administration of CsA was initially restricted to special cases because of its effect on
kidney function, observed with daily doses of 8–12 mg/kg. Today, with 20 years of expe-
rience with CsA, this drug has been shown to be well tolerated at daily doses below 5 mg/
kg. It is important to adjust the CsA dose to lean bodyweight; otherwise obese patients
would receive an excessive dose. Creatinine monitoring is essential to avoid renal toxicity.
If the CsA serum level is 1.4 mg/dl, the dose should be reduced; above that level the drug
should be discontinued. Individual tolerability of drugs must be considered in the final
drug combination used for maintenance therapy. Protocol:
– M-Th2
– Pred: 5 mg, 4 per week.
– CsA: 4 mg/kg per day, 6 days per week.
– MTX: 15 mg i.m. during alternate weeks. After 6 weeks without relapse, 10 mg p.o.
per week, on 3 nonconsecutive days, every other week.
– Folic acid: 5 mg per day, on 3 days after MTX.
– AZA: 100 mg per day, 6 days per week, during MTX-free weeks.
– ASA: 100 mg every evening.
Pregnancy and maintenance therapy
In patients without signs and symptoms of disease activity for at least 3 months, pregnancy
may be considered while taking low doses of Pred (45 mg per week), low doses of CsA
(3 mg/kg per day) on alternate weeks, and AZA (4100 mg per week) during the weeks
without CsA. HCQ can also be given during pregnancy. Strict obstetric supervision is es-
sential. After the 25th week of pregnancy pre-eclampsia (hypertension, albuminuria, or
edema) may occur. Rapid intervention is usually effective: bed-rest with the patient on her
left-side, 1 day with a strict low-protein, low-fat diet (just boiled potatoes, salt-free,
cooked apples, water or tea) and intestinal antimicrobial medication with paramomycin,
2250 mg, followed the next day by substitution of the intestinal flora by Bacillus acidi
lactici). Given at the first symptoms of pre-eclampsia, this therapy gives surprisingly good
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results. In the case of high creatinine levels CSA is discontinued and a few steroid pulses
(two or three) with 125 mg MP may be necessary. After the 32nd week close obstetric su-
pervision is essential to be prepared for a cesarian section. Breast-feeding is contraindicat-
ed. After delivery there is a tendency for autoimmune diseases to be exacerbated. Such re-
lapses can be prevented in most cases by an intravenous injection on day 10 with 15 mg
MTX plus 125 mg MP followed by maintenance therapy.
Monitoring of immunosuppressive therapy
Once the patient’s condition is clinically well characterized, the following laboratory tests
are essential to assess disease activity and possible drug toxicity: complete blood count,
erythrocyte sedimentation rate, creatinine, transaminases, g-glutamyl transpeptidase, and
standard urine analysis. At the same time blood pressure and body weight should be
recorded. The first control should take place after 2 weeks of treatment, then at monthly
intervals for 3 months, thereafter every 3 months.
Specific treatment protocols
Rheumatoid arthritis
Traditionally, patients with RA were given, for a long initial period, symptomatic treat-
ment with nonsteroidal anti-inflammatory drugs (NSAIDs). Finally, however, once the au-
toimmune nature of RA was established, early intervention with immunomodulatory drugs
became mandatory. The difficulty now resides in the assessment of early stages of RA,
particularly in patients with an insidious initial disease course without alteration of labora-
tory parameters. Fortunately, the spleen, an immunocompetent organ which is involved in
all collagen diseases, participates very early in the course of RA. Indeed, one of the first
signs of RA is a slight enlargement of the spleen, in general not detectable by echographic
examination but demonstrable by splenic percussion. The splenic percussion dullness is
very constant with a diameter of 5–6 cm diameter in healthy subjects. The strength of per-
cussion must be adjusted to the thickness of the fat-layer and attention paid to the differ-
ence between “pulmonary” and “abdominal” air sonority in order to detect the upper and
lower poles of the spleen with precision. The dimensions of the spleen can be accurately
measured using a linear echographic probe. Mild splenic enlargement (8–10 cm) occurs
before any disease-specific laboratory parameters appear. Strong splenic percussion pro-
duces a slight to moderate soreness, equal to or stronger than the sensation felt upon liver
percussion. In a more acute stage the patient may spontaneously complain of pain in the
splenic region. It is interesting to note that steroids, even if given daily for several months,
do not correct the splenic enlargement even though clinically the patient appears to be in
remission. In patients with joint involvement compatible with RA the finding of an en-
larged spleen may thus permit “early intervention” to be initiated if there is no other rea-
son for splenomegaly, for example, thalassemia intermedia and postmalaria splenomegaly.
The following protocols describe treatment regimes for RA according to clinical ex-
pression of disease.
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Mild forms of RA: moderate arthralgia with joint distribution typical for RA,
without joint effusion
Protocol:
– RA-Th1
– Pred: 10 mg 4 per week.
– CsA: 4.5 mg/kg per day in two equal doses, 6 days per week.
– MTX: 15 mg i.m. or i.v. per week for 1 month, subsequently every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– HCQ: 200 mg per day during MTX-free weeks.
Severe forms of RA
Severe forms: fever, swollen joints without effusion Protocol:
– RA-Th2
– Initiate treatment with 15 mg MTX + 40 mg DXM i.v. followed by:
– Pred: 15 mg 4 per week.
– CsA: 4.5 mg/kg per day in two equal doses, 6 days per week.
– MTX: 15 mg + 125 mg MP, i.v., 3 weeks out of 4; upon remission, MTX without
MP.
– Folic acid: 5 mg per day on 3 days after MTX.
– HCQ: 400 mg per day during MTX-free week.
Severe forms: swollen and warm joints, effusion in one or both knees Protocol:
– RA-Th3
– Arthrocentesis with aspiration of joint fluid and injection of 40 mg Depot Medrol
(MP) + 5 mg MTX in each knee.
– Initiation of treatment with 500 mg Cy + 125 mg MP in a 15- to 20-min perfusion
under adequate hydration.
– Continue with treatment regimen RA-Th2.
Severe forms: as in RA-Th2, with the possibility of using anti-TNF agents Protocol:
– RA-Th4
– Treatment regimen RA-Th2 + either etanercept or infliximab.
The efficacy of anti-TNF-a (infliximab and etanercept) has been well documented. In-
fliximab has a long half-life and thus can be administered with long intervals between in-
jections (4–8 weeks) but limits treatment flexibility. Etanercept with its short half-life al-
lows greater treatment flexibility and thus is to be preferred. Etanercept can be given as
subcutaneous injections at increasingly long intervals and discontinued when a stable clin-
ical remission is obtained.
Not all cases of RA are well-controlled with this regimen. This is especially so in pa-
tients who for long periods have received only symptomatic or insufficient immunosup-
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pressive treatment. In these cases several immunomodulatory drugs are available which
can be given in addition to the baseline therapy with Pred, CsA, MTX and HCQ:
– Lef, 20 mg per day. If well tolerated and efficacious after a 3-week trial, it may be con-
tinued for a long period.
– DP, 150 mg per day during the first week; if well tolerated, 300 mg per day for longer
periods.
– Thal, 100 mg (maximum 200 mg) per day. After 4 weeks Thal should be given every
other week. Prolonged treatment with Thal produces drug-resistance (after 4–
10 months). The addition of vitamin B1 and B6 may diminish the risk of peripheral neu-
ropathy. Alcohol should be strictly avoided.
– Anakinra, 1 mg s.c. per day (anakinra precludes the use of anti-TNF agents).
– SSZ, 500 mg two or three times per day.
– Dapsone, 25 mg per day for 1 week, subsequently 50 mg per day.
– Colchicine, 0.5 mg per day for 1 week; subsequently, if well tolerated, 1 mg per day.
With these seven drugs it is not yet possible to direct treatment according to the genetic
subtype of RA. For the time being we orient treatment empirically with drugs known to
interfere with the immune response. Lef is an effective immunomodulating agent but is
not tolerated by all patients. Low-dose DP has given surprisingly good results in many pa-
tients with few side reactions. The dose of 300 mg should not be exceeded. If there is no
improvement after 4 weeks, DP should be replaced by another immunosuppressive agent.
Low-dose Thal has been of great help in many cases. Initial results with anakinra, which
blocks the action of IL-1, are promising but experience is still limited with this drug. SSZ,
dapsone, and colchicine have proven useful in patients not responding well to the baseline
treatment.
Systemic lupus erythematosus
SLE is another autoimmune disease entity with a very wide spectrum of clinical expression,
a variability which probably depends on genetic background. In general the individual pat-
tern at onset of SLE tends to persist throughout the course of disease. Below are seven
treatment protocols for SLE, each intended for a specific clinical expression of the disease.
Mild forms of SLE: patients with arthralgia, butterfly rash, discrete kidney involvement,
and normal serum creatinine values
Protocol:
– SLE-Th1
– Pred: 10 mg per day, with 2 nonconsecutive Pred-free days per week.
– MTX: 15 mg i.m. per week for 4 weeks, subsequently every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– CsA: 4.5 mg/kg per day, 6 days per week.
– HCQ: 400 mg per day for 4 weeks, subsequently during MTX-free weeks.
– ASA: 100 mg every evening.
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ASA is given for the prevention of vascular accidents in all SLE patients, regardless of
whether antiphospholipid antibodies are present. After 2–3 months the Pred dose should
be reduced and MTX changed from intramuscular to oral administration, 10 mg per week
during alternate weeks on 3 nonconsecutive days.
Patients with nephrotic syndrome and normal creatinine values (1.3 mg/dl)
Protocol:
– SLE-Th2
– DXM: 40 mg i.v. on days 1, 3, and 5.
– MP: 125 mg i.v. on days 6, 8, 10, and 12.
– After day 12:
– Pred: 20 mg per day orally with 2 Pred-free days per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– MTX: 15 mg i.v. or i.m. per week, 3 weeks out of 4.
– Folic acid: 5 mg per day on 3 days after MTX.
– Cy: 500 mg + MP 125 mg in MTX-free weeks (as a slow infusion over 15–20 min)
until proteinuria falls below 1 g/l, subsequently every 8 weeks.
– ASA: 100 mg every evening.
Lupus nephritis with elevated serum creatinine (>1.5 mg/dl)
Protocol:
– SLE-Th3
– DXM: 40 mg i.v. on days 1, 3, 5.
– MP: 125 mg i.v. on days 6, 8, 10, and 12
– After day 12:
– Pred: 20 mg per day 5 days per week.
– CsA: after reduction of creatinine to 1.2 mg/dl, CsA 2.5 mg/kg per day for 1 week,
increasing to 3.5 mg/kg per day for 2–3 weeks, subsequently 4 mg/kg per day.
– Cy: when creatinine 2.5 mg/dl, 300 mg Cy + 125 mg MP i.v. When creati-
nine=2.0 mg/dl, 500 mg Cy + 125 mg MP alternating on a weekly basis with MTX.
– MTX: 10 mg i.m. or i.v. when creatinine <2.5 mg/dl, 15 mg i.m. or i.v. when creati-
nine <1.5 mg/dl, in alternation with Cy. After 4–6 weeks, MTX should be given 3
out of 4 weeks, Cy-MP i.v. infusion only during MTX-free weeks.
– Folic acid: 5 mg per day on 3 days after MTX.
– ASA: 100 mg every evening.
Adjustment of treatment according to clinical response. Cy-MP infusions diminished as
a priority (every 6–8 weeks, before complete discontinuation).
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SLE with cutaneous vasculitis, not responding to SLE-Th3
Protocol:
– SLE-Th4
– Addition of Thal, 100 mg every evening; after 4 weeks, on an alternate week basis.
– Dapsone: 25 mg b.i.d. during Thal-free weeks.
SLE with cardiac involvement (peri- or myocarditis) with or without pleural effusion
Protocol:
– SLE-Th5
– MP: 125 mg i.v. on alternate days during first week.
– Pred: (after 1st week) 20 mg per day with 2 nonconsecutive Pred-free days per
week.
– MTX: 15 mg + 125 mg MP i.v. 3 out of 4 weeks. After 6–8 weeks, MTX without
MP.
– Folic acid: 5 mg per day on 3 days after MTX.
– AZA: 100 mg per day during MTX-free weeks.
– CsA: 4.5 mg/kg per day, 6 days per week.
– ASA: 100 mg every evening.
SLE with “anti-phospholipid syndrome,” either deep vein thrombosis
or cerebral involvement
Protocol:
– SLE-Th6
– SLE-Th1 or SLE-Th5 protocol + oral anticoagulation ad vitam, maintaining an inter-
national normalized ratio level of 3–4, after 3 months between 2.5 and 3.5.
Special forms of neuro-lupus
Seizures. Convulsive seizures can antedate SLE or occur in the course of the disease. In
addition to basic SLE treatment, anticonvulsive medication is indicated for a prolonged
period of time, and especially for as long as EEG abnormalities are present.
Landry’s ascendant paralysis and acute transverse myelitis. These are rare but very seri-
ous complications in the course of SLE with the risk of permanent damage if not treated
properly [72]. Intrathecal treatment is very efficacious, if given immediately. Protocol:
– SLE-Th7
– DXM: 20 mg + 10 mg MTX, via lumbar puncture on days 1 and 8.
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– Cy: 500 mg + 125 mg MP as i.v. perfusion over 15–20 min on the day of intrathecal
treatment (days 1 and 8)
In addition, protocol SLE-Th5. In the case of relapse, intrathecal treatment must be re-
sumed.
Encephalopathy with hallucinations and/or comatose state. Same treatment as for Lan-
dry’s syndrome. Recurrences are common in this form of SLE encephalopathy (one pa-
tient relapsed 8 times, another patient 18 times; both were treated with intrathecal treat-
ment for each relapse, and both recovered after these series of relapses).
Chorea. Protocol SLE-Th5 with intrathecal treatment on days 1 and 8, each time in associ-
ation with Cy i.v. (see SLE-Th7).
Multiple sclerosis
MS is now generally accepted as a condition belonging to the autoimmune diseases. On
the one hand, these involve a multigenetically based spectrum of different forms of MS;
on the other, no other autoimmune disease is so strongly affected by environmental fac-
tors. Psychological events rank particularly high among the disease-triggering and dis-
ease-modifying factors, which renders the assessment of treatment efficacy in controlled
studies very difficult.
With these difficulties in setting up rational therapies, animal models of experimental
autoimmune encephalitis have been of great help. In experimental models CNS lesions
have been shown to be produced by specific T lymphocytes which first must penetrate the
blood-brain barrier in order to reach their target. This process is probably very similar in
MS patients. In contrast to all “collagen diseases,” none of the peripheral laboratory pa-
rameters is affected by the MS disease process. Normal values are found with regard to
inflammatory indicators; patients are not anemic and never show spleen enlargement.
The following clinical example illustrates this aspect. A 52-year-old woman developed
within a few months a very severe form of MS with diplopia, slurred speech, and great
difficulty in swallowing. She lost 8 kg in weight in 2 months. Steroid pulses with 31 g
MP were unsuccessful, as were plasmapheresis and high immunoglobulin pulses and high-
dose oral steroids. This patient consulted us in January 1992. Confronted with this desper-
ate situation, we hospitalized the patient for intrathecal treatment (20 mg DXM + 10 mg
MTX). The clinical response was dramatic, and the patient was able to leave the hospital
2 days later on mild maintenance therapy (low-dose steroids + MTX). Five weeks later
she relapsed but again responded to intrathecal treatment. After a further 6 weeks she re-
lapsed again. This time, an intravenous infusion of 500 mg Cy was added to the intrathecal
regimen. Furthermore, we added Cy-MP pulses to the maintenance therapy (500 mg Cy +
125 mg MP, every month). After 6 months without further relapse, pulses were given less
frequently, every 6 weeks, finally every 8 weeks, leaving a treatment of low-dose Pred
(45 mg per week) and MTX (15 mg intramuscularly in alternate weeks). Since then the
patient has remained in complete remission (last medical examination, 2003). This experi-
ence corroborates the situation in experimental autoimmune encephalitis. We postulate
that the role of Cy was to prevent MS-specific T and B cells from entering the CNS terri-
tory, and we now always give Cy pulses with an intrathecal treatment.
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As in all autoimmune diseases, early treatment is essential, particularly in conditions in
which there is the risk that irreparable damage may compromise the patient’s future. Early
diagnosis of MS is a prerequisite for the initiation of immunosuppressive therapy. Magnet-
ic resonance imaging (MRI) has become an essential tool for establishing a diagnosis of
MS at an early stage, thus permitting early initiation of therapy. However, in a small num-
ber of cases MRI may not reveal any demyelinated foci during the first months or even
years of the disease. In one of our patients with a typical clinical MS pattern the diagnosis
of MS was not accepted by the neurologists until, after 3 years and with progressive loss
of sight in one eye, the MRI finally showed some demyelinated foci at typical sites.
The distinction between “recurrent-remittent” vs. “primary progressive” forms of MS is
essential in the management of MS. In the recurrent-remittent form of the disease, re-
sponse to treatment is far better than in patients with the primary progressive form. Ac-
cordingly, different levels of treatment intensity are necessary for these two types of MS.
If untreated, recurrent-remittent MS may gradually transform into a primary progressive
course of disease, requiring a highly intensive treatment.
MS with a recurrent-remittent course of disease
In the majority of these patients the disease is characterized by self-limiting episodes fol-
lowed by remissions which may last months or years. If the first disease episode is fol-
lowed by a complete remission with normalization of all neurological findings observed in
the active phase of the disease, no preventive maintenance therapy is needed, but the pa-
tient must be aware of the possibility of future attacks, so that remission-induction treat-
ment can be given in the first days of a disease recurrence.
Remission induction in recurrent-remittent MS Protocol:
– MS-Th1
– DXM: 40 mg i.v. on days 1, 3, 5, 8, and 16
– Cy: 500 mg on days 1, 8, and 16 in an i.v. infusion over 15–20 min with adequate
hydration (1.5–2 l) + 25 mg furosemide to guarantee rapid elimination of Cy.
Maintenance treatment for recurrent-remittent MS, mild forms
– MS-Th2
– IFN-b1a: 36 106 U s.c. per week.
Treatment with IFN-b has yielded positive results, with diminution of the number of
relapses and diminution of progression as shown by MRI. IFN treatment is generally limit-
ed to 2 years. Monotherapy with IFN only acts on APC, leaving T and B lymphocytes un-
affected. In the case of relapse or signs of persistent disease activity, treatment should be
adjusted according to the severity of symptoms (MS-Th1 and MS-Th4).
– MS-Th3
– Glatiramer (acetate): 20 mg s.c. per day for long periods.
This treatment has been shown to reduce the frequency of relapses.
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Drug-combination maintenance therapy for mild to moderately severe forms of MS
Protocol:
– MS-Th4
– Pred: 45-10 mg per week.
– MTX: 10 mg per week, given p.o. over 3 nonconsecutive days per week, every other
week.
– Folic acid: 5 mg per day on 3 days after MTX days.
– AZA: 100 mg per day during MTX-free weeks.
The MS-Th4 approach permits more flexibility than MS-Th2 and MS-Th3. Depending
on the course of disease, the intensity of maintenance therapy can be increased by chang-
ing from oral to intramuscular administration of MTX (15 mg every other week) and by
adding CsA, 4 mg/kg per day, 6 days per week.
MS with a primary or secondary progressive course of disease
Treatment is initiated with remission-induction protocol.
Remission induction in primary progressive MS. Depending on the severity of disease at
the start of immunomodulating therapy, remission induction may be carried out according
to MS-Th1, or by intrathecal protocol MS-Th5. For patients with severe disease activity,
or progression of disease despite MS-Th6 maintenance therapy, see below. Protocol:
– MS-Th5
– Day 1:
20 mg DXM + 10 mg MTX intrathecal (by lumbar puncture)
Cy 500 mg + MP 125 mg i.v. infusion over 15–20 min.
Furosemide 25 mg
– Days 3, 4, 5:
40 mg DXM i.v.
– Day 8:
Intrathecal injection of 20 mg DXM + 10 mg MTX
500 mg Cy + 125 mg MP i.v. infusion over 15–20 min.
Furosemide 25 mg
– Day 16:
40 mg DXM i.v.
Maintenance therapy in primary progressive MS
Protocol:
– MS-Th6
– Pred: 45-10 mg per week.
– MTX: 15 mg i.m, 3 weeks out of 4.
– Folic acid: 5 mg per day, on 3 days after MTX.
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– CsA: 4 mg/kg per day, 6 days per week.
– Cy: 500 mg + MP 125 mg, i.v. infusion, + 25 mg furosemide, once every 4 weeks.
Depending on the course of disease, the intensity of maintenance therapy can either be
slowly reduced by increasing the intervals between Cy-MP pulses or increased by adding
100 mg Thal every evening during alternate weeks. In the event of disease exacerbation
the remission protocol MS-Th1 or MS-Th5 should be applied immediately because of the
risk of irreversible damage.
Autoimmune diseases with splenomegaly
In the following autoimmune conditions, mild splenomegaly reflects the systemic nature
of the disease: juvenile idiopathic arthritis, Still’s disease, uveitis, dermatomyositis, poly-
myalgia rheumatica, primary SjÛgren’s syndrome, progressive systemic sclerosis, Wege-
ner’s granulomatosis, Churg-Strauss syndrome, Crohn’s disease, ulcerative colitis, anky-
losing spondylarthritis, chronic active hepatitis, primary biliary cirrhosis, recurrent-remit-
tent pericarditis, interstitial pneumopathy, peripheral motor neuropathy, BehÌet’s syn-
drome, and sarcoidosis.
Juvenile idiopathic arthritis
Among the different forms of juvenile idiopathic arthritis the most frequent is juvenile
oligoarthritis (mono- or pauciarticular), with a 20% incidence of iritis. Less frequent are
polyarticular and enthetic arthritis, the latter corresponding to adult AS with a 5% inci-
dence of iritis. In children suffering from these conditions cortisone has produced the most
devastating effects, which are completely avoidable with drug combination therapy. In-
deed, the response to drug combination is particularly good in children, with an excellent
long-term prognosis on maintenance therapy generally limited to 5 years. Furthermore,
with this type of treatment, no child in the oligoarthritis group developed uveitis. The
spleen is enlarged on percussion in all children with active disease, palpable in only 25%
of affected children. The youngest patients are under 2 years of age. Protocol:
– JIA-Th
– Pred: 0.15 mg/kg per day, 4 days per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– MTX: 10 mg/m2 i.m. per week during alternate weeks.
– Folic acid: 0.05 mg/kg per day on 3 days after MTX.
– AZA: 1.5 mg/kg per day, 6 days per week during MTX-free weeks.
– Depending on the degree of disease activity, Etanercept may be added: 1 mg/kg
(max. 25 mg) s.c. twice per week for 4 weeks, subsequently increasing the interval
between injections from 4 to 7 days until complete remission.
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Still’s disease
In 1897 Still described a systemic disease with high fever, lymphadenopathy and spleno-
megaly (80%), PC, and/or pleurisy (35%), iritis (10%) and arthritis of the larger joints.
White blood cell values can reach 20,000–30,000. This serious condition occurs mostly in
children but occasionally also in young adults.
Treatment protocol R-Th2 followed by M-Th2 for maintenance is generally effective
and produces minimal side effects. Two-thirds of patients experience permanent complete
remission.
Idiopathic autoimmune uveitis
Anterior uveitis (iritis and iridocyclitis) as well as posterior uveitis (choroiditis and chorio-
retinitis) can occur in patients with systemic autoimmune diseases but can also occur alone
as “idiopathic” autoimmune uveitis (UV). The presence of a mild splenomegaly in this id-
iopathic form reflects its systemic character. Treatment of uveitis must take into account
the systemic nature of the disease. Local therapy is certainly not sufficient to bring uveitis
under control. Patients with anterior uveitis have ocular and periocular pain with lacrima-
tion as well as photophobia with circumcorneal injection. In the case of posterior uveitis,
blurred vision and metamorphopsia with reduction in visual acuity are the main symp-
toms.
Both forms of uveitis respond to immunosuppressive therapy according to protocol R-
Th2. Maintenance therapy (M-Th2) is necessary for a period of 1–5 years. Relapses are
not infrequent and require an immediate remission-induction regimen.
Dermatomyositis
Dermatomyositis (DM) is a systemic connective tissue disease which affects mostly chil-
dren in the 5- to 15-year age group and less frequently adults between the ages of 40 and
60 years. It is characterized by inflammatory changes in muscles (polymyositis) and, par-
ticularly in children, in the skin. The cutaneous eruption may resemble the lupus butterfly
rash. Periorbital edema with a heliotrope hue are typical for DM, as is erythema localized
in the V of the neck, shoulders, forearms, legs, and dorsum of proximal interphalangeal
and metacarpophalangeal joints. Transition from DM to progressive systemic sclerosis
(PSS) and SLE can occur. The skin lesions fade under immunosuppressive therapy. Sub-
cutaneous calcifications may develop at typical sites (elbows and knees), particularly in
childhood dermatomyositis. In adults the disease may be limited to the muscles with prox-
imal muscle weakness and polymyalgia, always with elevation in muscle enzymes, espe-
cially creatinine phosphokinase. Tumor screening should be performed in patients aged
over 50 years since DM can represent a paraneoplastic (usually carcinoma) condition.
Treatment: early intervention with remission-induction protocol R-Th2. Maintenance
therapy is necessary for a long period of time, usually several years (M-Th1 or M-Th2).
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Polymyalgia rheumatica
This chronic condition is known to respond readily to steroids. However, continuous dis-
ease activity requires a prolonged treatment entailing a high risk of cortisone side effects,
especially in patients over 50 years of age. Thus, “traditional” steroid monotherapy has to
be abandoned. The disease process can be brought under control with minimum side ef-
fects by drug combination therapy of polymyalgia rheumatica using protocol R-Th1 or R-
Th2.
Maintenance treatment is necessary for a long time, usually several years, with protocol
M-Th1 or M-Th2 depending on the degree of disease expression.
Primary SjÛgren’s syndrome
Mild splenomegaly is present even in the early stages of this condition, which involves
lacrimal, salivary gland, and vaginal secretion. Interstitial nephritis rarely affects renal
function. The lacrimal glands are the most vulnerable target of the disease since their num-
ber is very limited, augmenting the danger of irreparable loss of lacrimation with corneal
lesions.
Early intervention by protocol R-Th2 is usually effective. Under CsA medication ocular
bruising may subside after only 10 days of treatment, although prolonged treatment is nec-
essary in most cases. Maintenance therapy: M-Th2.
Progressive systemic sclerosis
The scleroderma spectrum encompasses multiorgan disease processes with alteration in
the microcirculation. The disease may be limited to the skin or affect simultaneously or
separately the gastrointestinal tract, pulmonary system (interstitial pneumopathy, IP),
heart, and kidney (microangiopathy with malignant hypertension). More common in wom-
en, rare in children, mortality in PSS is almost ten times higher than in SLE.
PSS limited to skin involvement. Protocol:
– PSS-Th1
– Pred: 45 mg per week.
– CsA: 4.5 mg/kg per day (contraindicated in the case of hypertension).
– MTX: 15 mg i.m. every other week.
– Folic acid: 5 mg per day on 3 consecutive days after MTX.
– DP: 1 or 2150 mg per day.
– ASA: 100 mg every evening.
Local treatment of affected skin: massage with cream containing ASA and heparin or
heparinoid to prevent ulcers on finger-tips. For extensive and severe skin involvement
symptomatic treatment with infusions of prostacyclin analogues produces temporary im-
provement in the microcirculation. Maintenance therapy: M-Th2.
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PSS with IP and/or esophago-gastrointestinal involvement. IP is a very serious condition
which fortunately may respond to early intervention (characteristic signs of pulmonary
auscultation!). Esophago-gastrointestinal involvement can be most troublesome, not only
for mechanical reasons but also because of the consequences of “malabsorption.” For this
reason, oral antibiotics may be ineffective in cases of severe infection. These patients often
feel an improvement upon parenteral administration of vitamins B1, B2, B6, and B12. Pro-
tocol:
– PSS-Th2
– Pred: 10 mg, 5 days per week.
– CsA: 4.5 mg/kg per day, 6 days per week (with strict control of blood pressure
which, if necessary, must be corrected with a thiazide diuretic and an antiangiotensin
receptor agent).
– MTX: 15 mg i.m. per week for 4 weeks, subsequently every other week.
– Folic acid: 5 mg per day for 3 days after MTX.
– Cy: 500 mg + 125 mg MP in a 15- to 20-min infusion with adequate hydration, dur-
ing MTX-free weeks, once per month until remission is reached.
– DP: 150 mg b.i.d.
– ASA: 100 mg every evening.
– Vitamin B complex: i.m. 2 per week for 2 months, subsequently once per week.
Gradual adjustment of treatment intensity. Life-long maintenance treatment (M-Th2) is
necessary for this severe form of PSS.
PSS with malignant hypertension and symptoms of left-ventricular failure. Protocol:
– PSS-Th3
– PSS-Th2 protocol without CsA.
Antihypertension treatment is essential to rectify blood pressure. Maintenance therapy:
M-Th1.
Wegener’s granulomatosis
This granulomatous inflammatory disease is initially localized in the upper respiratory
tract, gradually extending to become a systemic vasculitis. Kidney involvement may lead
to renal failure in the absence of early immunosuppressive treatment which is essential to
prevent this detrimental course of disease. Oral administration of Cy has been used with
some success for the treatment of this condition, but toxicity is high and benefit limited.
Cy is nevertheless the most effective drug if administered in intravenous pulses in combi-
nation with other immunomodulatory drugs. Protocol:
– WEG-Th
– Pred: 10 mg, 4 days per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– Cy: 500 mg + MP 125 mg, in an i.v. infusion over 15–20 min with adequate hydra-
tion. Initially every other week for 6 weeks, subsequently every 4 weeks.
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– MTX: 15 mg i.m. during Cy-free weeks.
– Folic acid: 5 mg per day on 3 days after MTX.
– ASA: 100 mg every evening.
Close surveillance of the respiratory tract is necessary. In the case of infection antibiot-
ic therapy must be started immediately. Maintenance treatment: M-Th2.
Churg-Strauss eosinophilic granulomatous syndrome
Initially this condition involves the respiratory tract long before the appearance of system-
ic disease manifestations such as patchy pulmonary infiltrates. Other systemic symptoms
such as peri- and/or myocarditis, attacks of intestinal involvement, and peripheral neurop-
athy may occur. At the onset patients complain of nasal respiratory difficulty (presence of
nasal polyps), asthma attacks, and chronic cough. Without proper treatment there is a high
mortality rate. The degree of eosinophilia usually reflects disease activity. The spleen is
slightly enlarged and tender on percussion. Protocol:
– CHURG-Th
– Pred: 15 mg, 5 days per week for 1 month, subsequently 4 days per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– MTX: 15 mg + 125 mg MP i.v. once per week for 1 month; subsequently every oth-
er week, i.m. without MP.
– Folic acid: 5 mg per day on 3 days after MTX.
– AZA: 100 mg per day during MTX-free weeks.
– ASA: 100 mg every evening.
Otorhinolaryngological intervention is advisable to remove polyps, usually located
around the ostia of the maxillary sinuses.
Maintenance therapy: M-Th2.
Crohn’s disease
This granulomatous inflammatory condition primarily involves the terminal part of the ile-
um with possible extension in both directions. Its systemic nature is reflected in the en-
largement of the spleen and in extraintestinal manifestations including arthritis, episcleritis
and erythema nodosum. If untreated, the disease process may produce a stenosis of the ter-
minal ileum, severe enough to require surgery. Early intervention is thus essential. Since
TNF-a is relevant in this inflammatory process, anti-TNF agents are potentially useful for
remission induction. Protocol:
– Crohn-Th
– Pred: 410 mg per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– MTX: 15 mg i.m. every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– AZA: 100 mg per day, 6 days per week during MTX-free weeks.
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– SSZ: 1 g t.i.d.
– ASA: 100 mg every evening.
– Etanercept: for remission induction in the event of acute attacks, 25 mg s.c. twice
per week.
Since the immune conflict takes place in a microbe-rich environment, with microbes as
potential disease-triggering and disease-modifying factors, intermittent local antimicrobial
treatment is advisable: 250 mg metronidazole t.i.d. during episodes of disease activity,
and/or, 250 mg paromomycin twice on 1 day only, with a light protein-free diet (e.g.,
steamed potatoes and steamed apples) with administration of Bacillus acidi lactici on the
following day. In the event of a positive result, this procedure may be repeated twice per
month.
Maintenance therapy (M-Th2) is necessary for a long period, in general 3–5 years. In
the case of relapse, treatment protocol Crohn-Th should be resumed immediately.
Ulcerative colitis
The target of this systemic granulomatous autoimmune disease is the distal colon and the
rectum. The spleen is always slightly enlarged in active stages of the disease. Extracolonic
involvement includes peripheral arthritis, sacroileitis, erythema nodosum, uveitis, and
spondylitis. Both ankylosing spondylitis and uveitis have a strong association with the
HLA antigen B-27. As in Crohn’s disease, TNF-a is implicated in the inflammatory pro-
cess, justifying the use of anti-TNF agents. Crohn-Th protocol is equally applicable for
UC, including the use of paromomycin.
Ankylosing spondyloarthritis
The primary target of AS is the spine, in particular the apophyseal vertebral joints, para-
vertebral soft tissues, and sacroiliac joints. In later stages peripheral joints may be affect-
ed. Iritis occurs in about 10% of cases, especially in patients with the histocompatibility
antigen HLA-B27. Both Crohn’s disease and UC may be associated with AS. Response to
immunosuppressive therapy is weak; nevertheless the Crohn-Th protocol is worth trying.
Since TNF-a is an important mediator of inflammation in AS, anti-TNF therapy should be
considered in patients with severe clinical activity.
Chronic active hepatitis
In this autoimmune disease, environmental factors are of primary importance. “Idiopathic”
HCV- and HBV-negative chronic active hepatitis (CAH) is infrequent. Indeed, most pa-
tients with CAH are HCV positive and, to a lesser degree, HBV positive. Treatment of the
viral condition must be undertaken (pegylated IFN plus ribavirin in hepatitis C, lamivudin
for hepatitis B), together with immunosuppressive treatment of CAH. It should be borne
in mind that IFN, necessary for the treatment of hepatitis C, has a negative effect on auto-
immune hepatitis (increase in transaminases and hypergammaglobulinemia). In patients
failing to respond to antiviral treatment, long-term immunosuppressive therapy of CAH is
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necessary in view of the possible progression into hepatic cirrhosis. Since the hepatic in-
flammatory process of chronic hepatitis C is mediated by the ongoing, albeit unsuccessful,
antiviral immune response, and not by a direct viral action, immunosuppressive therapy is
not contraindicated in patients carrying HCV. In fact, it diminishes the antiviral phlogistic
process as well as the autoimmune activity of CAH.
In patients with persistence of HCV-RNA, prevention of viral expansion under immu-
nosuppressive therapy may be attempted with antiviral medication (200 mg ribavirin t.i.d.
+ 100 mg amantadine b.i.d.). Protocol:
– CAH-Th
– If transminase levels are elevated to more than 60 U/l alanine aminotransferase,
treatment is initiated by i.v. pulses of 125 mg MP, every other day, followed by oral
therapy:
– Pred: 15 mg, 4 per week. After 1 month, 10 mg 4 per week.
– CsA: 4 mg/kg per day, 6 days per week for 2 months; subsequently on an alternate
week schedule.
– 6-MP: 50 mg per day, 6 days per week for 2 months; subsequently during the CsA-
free weeks.
– ASA: 100 mg every evening.
Maintenance therapy: M-Th2.
Primary biliary cirrhosis
Initially, this autoimmune disorder involves lymphocytic infiltration of medium-size bile
ducts and portal tracts. Untreated, patients with primary biliary cirrhosis (PBC) develop
slowly progressive fibrosis, finally leading to liver cirrhosis. The skin is pigmented and
tanned as a result of melanocytic stimulation. Elevation in alkaline phosphatase and bile
acids cause pruritus. The spleen is slightly enlarged in untreated patients. Immunosuppres-
sive therapy has given controversial results, but none of our patients lost liver function un-
der drug-combination therapy, including two patients who were already on the waiting-list
for a liver transplant. Protocol:
– PBS-Th
– Pred: 5 mg, 4 per week.
– CsA: 4 mg/kg per day, 6 days per week.
– DP: 150 mg o.d., after 1 week b.i.d. or t.i.d., 6 days per week.
– Colchicine: 0.5 mg per day for 1 week, subsequently 1 mg per day.
– MTX: 15 mg i.m. per week for 1 month, subsequently every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– 6-MP: After 1 month of treatment with Pred, CsA, DP, MTX, folic acid, start 6-MP
50 mg per day during MTX-free weeks.
– Ursodeoxycholic acid: 300 mg b.i.d. (for relief from pruritus).
– ASA: 100 mg every evening.
Upon remission, treatment should be gradually adjusted according to clinical results.
Treatment is necessary for at least 4 years.
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Recurrent-remitting pericarditis
The presence of slight splenomegaly permits to integrate this syndrome into the group of
autoimmune conditions. Remission induction therapy protocol:
– PC-Th
– MP: 125 mg on days 1, 2, 4 and 6, followed by:
– Pred: 5 mg 4 per week.
– CsA: 4 mg/kg per day, 6 days per week.
– MTX: 15 mg i.m. every other week. After 6 months without relapse, stop MTX.
– Folic acid: 5 mg per day on 3 days after MTX.
– ASA: 100 mg every evening.
Long-term maintenance therapy with M-Th1 or M-Th2 is necessary.
Interstitial pneumopathy
This autoimmune condition can occur in isolation, without any other organ involvement
except mild splenomegaly. Long-term immunosuppressive treatment is indicated. Proto-
col:
– IP-Th
– Pred: 5 mg 4 per week.
– CsA: 4 mg/kg per day, 6 days per week.
– MTX: 15 mg i.m. every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– DP: 150 mg per day for 1 week; subsequently b.i.d., 6 days per week.
– ASA: 100 mg every evening.
In the event of pharyngobronchitis, immediate antibiotic treatment is indicated (e.g.,
400 mg moxifloxacin per day for 5 consecutive days).
Peripheral motor neuropathy
In contrast to amyotropic lateral sclerosis, which is primarily a motor neuron disease with
gradual loss of spinal motor neurons, peripheral motor neuropathy (PMN) affects the mo-
tor nerve axon or its myelin sheath. Sensory neuropathy may accompany PMN. Unlike in
amyotropic lateral sclerosis, slight splenomegaly is present in PMN patients. Early immu-
nosuppressive intervention is necessary to prevent irreparable damage. Protocol:
– PMN-Th
– Pred: 10 mg 4 per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– Cy: 500 mg + 125 mg MP i.v. in a 15–20 min infusion with adequate hydration:
once per month.
– MTX: 15 mg i.m. per week, for 3 consecutive weeks out of 4, for 2 months; subse-
quently every other week.
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– Folic acid: 5 mg per day on 3 days after MTX.
– ASA: 100 mg every evening.
BehÌet’s syndrome
BS is a multisystem inflammatory disorder with mucocutaneous manifestations (painful
mouth and genital ulcers, erythema-nodosum-like lesions) and variable involvement of the
eyes, joints, CNS, and gastrointestinal tract. With regard to ocular involvement the most
common lesion is relapsing iridocyclitis, but the posterior segment may also be involved
with choroiditis, retinal vasculitis, and papillitis. There is a 2:1 male:female ratio in BS.
Response to immunosuppressive therapy is variable. Treatment regimens must be flexible
and adjusted according to the severity of the disease. Protocol:
– BS-Th
– Pred: 10 mg 5 times per week for 1 month; subsequently 4 per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– Colchicine: 1 mg per day, 6 days per week.
– MTX: 15 mg i.m. per week for 1 month; subsequently every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– AZA: 100 mg per day, 6 days per week during MTX-free weeks.
– Cy: 500 mg + MP 125 mg in a 15- to 20-min infusion with adequate hydration, once
per month during MTX-free week. Cy is only added for patients not responding well
to the combination of Pred, CsA, colchicine, MTX and AZA.
– ASA: 100 mg every evening.
Long-term maintenance treatment: protocol M-Th2 plus colchicine.
Sarcoidosis
Sarcoidosis is a multisystem granulomatous disorder characterized histologically by epith-
eloid tubercles without necrotic foci. The lungs may show diffuse infiltrates and mediasti-
nal adenopathy. The spleen is always enlarged on percussion. Additional disease manifes-
tations include granulomatous uveitis, arthritis, CNS (especially facial paralysis), and
asymptomatic hepatic granulomas.
Immunohistologically sarcoidosis is characterized by granulomatous lesions involving
APC (“epitheloid cells”) and T and B lymphocytes. Drug-combination therapy must there-
fore be aimed at these cell types. Cortisone monotherapy has been shown to be useful, but
ineffective in severe cases, particularly in patients with granulomatous uveitis. Further-
more, long-term cortisone monotherapy produces unacceptable side effects.
Remission induction: protocol R-Th2. Maintenance treatment: protocol M-Th2 for 1–
5 years.
Antibody-mediated autoimmune diseases
The following conditions are mediated by a direct and selective antibody attack on the re-
spective targets: autoimmune hemolytic anemia, autoimmune thrombocytopenia, pemphi-
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gus (PEM), bullous pemphigoid (BPEM), and MY. The severity of the disease depends on
quantity and quality of antibodies. Treatment is directed primarily towards the antibody-
producing B cells but also towards the regulation of B cell activity via APC and T lympho-
cytes. Early intervention is again of utmost importance to prevent clonal expansion of an-
tigen-driven autoreactive B cells. Clonal expansion not only increases the number of anti-
body-forming B cells but also modifies the nature of the antibodies. Ongoing somatic mu-
tations lead to the selection of B cells with increased binding strength of antibodies to re-
spective targets, thus augmenting the pathogenicity of the autoimmune process.
In very severe clinical conditions, rapid remission induction can be achieved by me-
chanical removal of antibodies and simultaneous inhibition of antibody production (proto-
col AB-Th1) Protocols:
– AB-Th1
– Apheresis with removal of 3 l of plasma on days 1, 3, and 5.
– Cy: 500 mg + 125 mg MP (or 40 mg DXM) on days 4 and 11, in a 15- to 20-min
infusion with appropriate hydration.
– Ig: 1 g/kg in slow i.v. infusion on day 5 or 6.
Maintenance treatment as of day 12 is with protocol A5-Th2.
– AB-Th2
– Pred: 20 mg, 5 per week. After 2–3 weeks, gradual diminution of doses to 10 mg,
5 times per week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– MTX: 15 mg i.m. every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– AZA: 100 mg per day, 6 days per week during MTX-free weeks.
– Cy: 500 mg + 125 mg MP in a 15- to 20-min infusion with adequate hydration, once
per month during MTX-free week (only if above drug combination yields insuffi-
cient result).
Autoimmune hemolytic anemia
In Coombs’ positive AIHA, antibody production may occur as part of a systemic autoim-
mune disease such as SLE, in the course of chronic lymphocytic leukemia, or as an “iso-
lated” autoimmune condition. AIHA may be the first disease manifestation of SLE, some-
times years before the systemic development of SLE. The presence of hypergammaglobu-
linemia and/or of antinuclear antibodies is predictive of such a course. The antibody-coat-
ed red cells are eliminated in the spleen, which becomes enlarged as a consequence of
massive phagocytosis of red cells. The degree of splenomegaly in idiopathic AIHA re-
flects the duration and importance of red cell sequestration.
Remission induction: protocol AB-Th1 is generally not necessary in early intervention
in AIHA. The following remission-induction regimen may be sufficient:
– AIHA-Th1
– DXM: 40 mg i.v. on days 1, 2, 4 and 6.
– MP: After day 6, 125 mg i.v. every other day for 1–2 weeks.
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– Cy: 500 mg in a 15-min infusion on day 1 together with DXM, and on day 8 with
MP.
Maintenance treatment protocol: AIHA-Th2 after day 6:
– AIHA-Th2
– Pred: When i.v. MP has been stopped, oral administration of 20 mg, 5 days per
week.
– CsA: 4.5 mg/kg per day, 6 days per week.
– Colchicine: 1 mg per day, 6 days per week.
– MTX: initiation 1 week after second Cy infusion, 15 mg i.m. every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– ASA: 100 mg every evening.
Maintenance treatment is adjusted according to clinical response. Colchicine, if well
supported, should be given for a long period of time, at least as long as the spleen is en-
larged, and the number of reticulocytes is above 1.7% of red blood cells. Relapses may
occur after years in remission.
Idiopathic thrombocytopenic purpura
Thrombocytopenic purpura without any apparent exogenous cause is relatively common,
particularly in children with self-limiting thrombocytopenia. In fewer than one-third of
children, but in the majority of adults, thrombocytopenia has a chronic course. ITP may be
combined with AIHA or be part of a systemic autoimmune disease, especially SLE. It can
actually be the first sign of SLE, years before it is diagnosed. Thrombocytopenia can also
be part of the antiphospholipid syndrome. Splenomegaly, which is absent in ITP, indicates
in all these systemic conditions the presence of an underlying connective tissue disorder.
Remission induction: protocol AB-Th1 or AIHA-Th1 may be used, depending on the
severity of the condition. In severe childhood thrombocytopenia, high-dose immunoglobu-
lin has been shown to yield positive results (400 mg/kg per day for 3–4 days, or 1 g/kg as
a single infusion). In the past, splenectomy was frequently performed in the management
of ITP. With the improvement in therapeutic means, splenectomy is now performed only
in patients not responding to drug combination therapy. It is contraindicated in patients un-
der 20 years of age.
Maintenance treatment: protocol AIHA-Th2 is also suitable for the management of ITP
but without colchicine (this drug has not shown any therapeutic activity in the treatment of
ITP).
Pemphigus
PEM is a potentially fatal skin disorder, which also affects (sometimes exclusively) the
buccal mucosa. Autoantibodies are directed against desmogleine 3, which is responsible
for the interconnection of epithelial cells in the skin and in the epithelium of the mouth.
These antibodies can be revealed by an indirect diagnostic immunofluorescence test on
skin sections; positive results can also be obtained with serum from patients with PEM
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limited to buccal lesions. Today PEM can be brought under control with drug combination
therapy, provided treatment is initiated at a very early stage of the disease. If the skin le-
sions are permitted to spread without treatment, the danger of infection increases, especial-
ly in patients on cortisone medication.
Remission induction: in severe cases with rapidly progressive skin lesions, protocol
AB-Th1 represents a very effective approach. Protocol PEM-Th1 is less invasive. Proto-
col:
– PEM-Th1
– MP: 250 mg i.v. on days 1 and 2, subsequently 125 mg on days 4, 6 and 8.
– After day 8, maintenance treatment PEM-Th2.
MM, shown to be particularly effective in some PEM patients, should be included in
long-term treatment regimens at doses tolerated by individual patients. Thal has also been
useful in controlling disease activity. Protocol:
– PEM-Th2
– Pred: 20 mg, 5 days per week for 2 weeks, subsequently 4 days per week, with grad-
ual diminution of the daily dose from 20 to 10 mg.
– CsA: 4.5 mg/kg per day, 6 days per week.
– MTX: 15 mg i.m. every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– Cy: 500 mg + 125 mg MP in a 15- to 20-min infusion with appropriate hydration,
once per month during an MTX-free week.
– MM: 500 mg b.i.d., if well tolerated, t.i.d.
– Thal: 100 mg 6 times per week for 1 month; subsequently every other week.
– ASA: 100 mg every evening.
Adjustment of treatment intensity according to diminution of disease activity.
Bullous pemphigoid
BPEM is a chronic bullous eruption seen mainly in the elderly. In this condition autoanti-
bodies are directed towards the basement membrane of the epidermis. The mouth is never
involved. BPEM is a much less severe disease than PEM. No special remission-induction
procedure is generally necessary. Long-term treatment protocol:
– BPEM-Th
– Pred: 15 mg 5 per week for 4 weeks, subsequently 4 per week with gradual dimi-
nution of daily dose from 15 to 10 mg.
– CsA: 4 mg/kg per day, 6 days per week.
– MTX: 15 mg i.m. every other week.
– Folic acid: 5 mg per day on 3 days after MTX.
– MM: 500 mg b.i.d., 6 days per week for 4 weeks, subsequently every other week.
– AZA: 100 mg per day, 6 days per week, every other week.
– Thal: 100 mg per day, 6 days per week for 4 weeks, subsequently every other week
(weeks without AZA).
– ASA: 100 mg every evening.
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Upon remission, treatment should be gradually diminished. Thal should be the first
drug to be stopped, subsequently according to individual drug tolerability.
Myasthenia gravis
MY is caused by autoantibodies against acetylcholine receptors of the neuromuscular
junction. The disease may affect patients of any age, with two peaks, one in adolescents
and young adults, the other in adults over the age of 40 years. The condition shows a
strong relationship with tumors of the thymus, sometimes too small to be visualized on
MRI. Today thymectomy is performed in most patients under the age of 50 years, also
without detectable enlargement of the thymus. The results of thymectomy are unpre-
dictable; in some patients it leads to improvement, in a few to permanent cure. In general,
MY is a disease limited to the action of antibodies against the acetylcholine receptor.
However, in a small proportion of patients, MY is part of a systemic autoimmune disease
with arthralgia, splenomegaly, and presence of anti-nuclear antibodies. Clinical expression
of MY chiefly concerns muscles innervated by cranial nerves with a variable disease in-
tensity, from very mild to very severe.
In very mild cases treatment is in general limited to cholinesterase inhibitory drugs. In
very seriously affected patients, with life-threatening signs of respiratory distress, remis-
sion-induction protocol AB-Th1 is indicated, possibly requiring more than three plasma-
pheresis sessions. Subsequently, protocol AB-Th2 may be applied with gradual diminution
of medication according to regression of disease symptoms.
Maintenance treatment: protocol M-Th1 or M-Th2 may be sufficient. Simultaneous ad-
ministration of cholinesterase-inhibiting drugs may be necessary (neostigmine or pyrido-
stigmine).
Conclusions
During the past 50 years much has been accomplished in the definition and understanding
of autoimmune diseases in terms of genetics, mechanisms of disease, and the role of envi-
ronmental factors. The conditions for a rational treatment of autoimmune diseases thus
seem to be at hand with the ever-increasing number of drugs acting at different levels of
the immunopathological process. What then renders the clinical application of this scien-
tific progress so difficult?
1. Generally in today’s medical practice one expects strict treatment protocols. Howev-
er, such protocols are not suited to the treatment of chronic autoimmune diseases, variable
from patient to patient and even within the same patient during the course of disease.
2. Compartmentalization between the numerous fields of medicine has created great
barriers between the various clinical specialties, rendering difficult the exchange of treat-
ment experience between fields.
3. Consideration must be given to the fact that, for pharmacogenetic and/or environ-
mental reasons, a given drug (with well-defined activity and toxicity) is not equally well
accepted by all patients. Hence there is the need to use alternative drugs in cases of intol-
erance.
4. Diagnosis and treatment is commonly based on immunological parameters which re-
present humoral (B cell) markers. This is justified in autoimmune diseases such as AIHA,
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where damage is caused by these antibodies. However, in the majority of autoimmune dis-
eases there is a prevalence of T cell pathology for which no diagnostic T cell laboratory
tests exist. In T cell dependent pathologies such as RA, systemic sclerosis, SjÛgren’s syn-
drome, and Wegener’s granulomatosis, lack of B cell markers does not, as commonly
thought, necessarily indicate absence of disease activity. With this misinterpretation, the
danger exists that the opportunity for early therapeutic intervention will be missed. Con-
versely, persistence of these B cell markers does not necessarily indicate disease activity.
What can be done to improve the clinician’s therapeutic approach to autoimmune
pathologies? He must first abandon his belief in rigid treatment protocols. The principle of
“flexible treatment regimens” must be understood and applied as the logical consequence
of the great variability in autoimmune disease expression.
The creation of centers for the treatment of autoimmune diseases would permit a broad
therapeutic approach to patients suffering from a multitude of autoimmune conditions.
However, the compartmentalization of medicine in university and hospital structures
makes such an undertaking impossible.
Transversal study groups could provide the infrastructure for the transfer of treatment
results from one sector to another. As the most frequent autoimmune disorders are located
within the territories of rheumatology and neurology, these two fields could become the
core of such a transversal autoimmune group. Success of treatment depends to a great ex-
tent on active collaboration between patient and physician. In addition, an interdepartmen-
tal autoimmune study group could create an information center for patients, as has been
done successfully for diabetics and hypertensives. Indeed, patients suffering from chronic
diseases should be well informed about their illness and the action of the drugs prescribed
for them.
Appendix
List of 43 autoimmune diseases
– Alopecia totalis
– Ankylosing spondyloarthritis
– Anticardiolipin syndrome
– Aplastic anemia
– Autoimmune hemolytic anemia
– Basedow’s disease
– BehÌet’s syndrome
– Bullous pemphigoid
– Chronic active hepatitis
– Churg Strauss syndrome
– Cogan’s syndrome
– Crohn’s disease
– Cryoglobulinemia
– Dermatomyositis
– Discoid lupus erythematosus
– Hashimoto thyroiditis
– Idiopathic interstitial pneumopathy
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– Idiopathic thrombocytopenic purpura
– Juvenile idiopathic arthritis
– Lambert-Eaton myasthenic syndrome
– Lichen planus
– Motor neuron disease with splenomegaly
– Multiple sclerosis
– Myasthenia gravis
– Nephrotic syndrome with splenomegaly
– Pemphigus
– Pericarditis, idiopathic with splenomegaly
– Polyarteritis nodosa
– Polymyalgia rheumatica
– Polymyositis
– Primary biliary cirrhosis
– Psoriasis
– Rheumatoid arthritis
– Sarcoidosis
– SjÛgren’s disease
– Still’s disease
– Systemic lupus erythematosus
– Systemic sclerosis
– Takaiasu arteritis
– Ulcerative colitis
– Uveitis, idiopathic with splenomegaly
– Weber-Christian disease
– Wegener’s granulomatosis
Abbreviations used in the text
AIH autoimmune hepatitis
AIHA autoimmune hemolytic anemia
APC antigen-presenting cells
AS ankylosing spondyloarthritis
ASA acetylsalicylic acid
AZA azathioprine
BPEM bullous pemphigoid
BS BehÌet’s syndrome
CAH chronic active hepatitis
CD cluster of differentiation
CsA cyclosporine A
Cy cyclophosphamide
DC dendritic cells
DM dermatomyositis
DP d-penicillamine
DXM dexamethasone
EBV Epstein-Barr virus
HCQ hydroxychloroquine
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HCV hepatitis C virus
HLA human leukocyte antigen
IFN interferon
IL interleukin
IP interstitial pneumopathy
ITP idiopathic thrombocytopenic purpura
JIA juvenile idiopathic arthritis
Lef leflunomide
LKM liver-kidney microsomal
MHC major histocompatibility complex
MM mycophenolate mofetil
MP methylprednisolone
6-MP 6-mercaptopurine
MRI magnetic resonance imaging
MS multiple sclerosis
MTX methotrexate
MY myasthenia gravis
NSAID nonsteroidal anti-inflammatory drug
PBC primary biliary cirrhosis
PC recurrent-remitting pericarditis
PEM pemphigus
PMN peripheral motor neuropathy
Pred prednisone
PSS progressive systemic sclerosis
RA rheumatoid arthritis
RF rheumatoid factor
SLE systemic lupus erythematosus
SSZ sulfasalazine
TCR T cell receptor
Th T helper
Thal thalidomide
TNF tumor necrosis factor
UC ulcerative colitis
UV idiopathic autoimmune uveitis
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